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TITLE ABSTRACT 
COMPUTERIZED DHUG-DRUG I NTERACTION FILE 
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ABS'J'.RACT 
The project was designed to organiz e and develop a comput-
erized drug-drug intera ction file. The methodology for the organ-
ization, storage and retrieval of drug-drug interaction information i s 
discussed. In order to accor.nplish this objective several requirements 
were met. Th8y are a s folimvs: (1) Seleciion and evaluation of clin-
ically significant drug-drug interactions from the scientific literature, 
(2) C reation of a computerized data bank for drug-drug interactions, 
and (3) Design and developm e nt of a computerized printout which 
reports the i nformation in concise s ummaries. 
The n le i s designed to be compatible wit h existing comput.-
erized record keeping and drug informa tion systems. In addition, 
the retrieval system has several unique cha racteristi cs. The re-
porti ng format is designed t o p r o vide practical drug-drug interaction 
i nforrnation in a concise summary which can be easily understood 
and utili zed by either a physician or pharmacist in a patient care 
environment. It will provide the clinical pharmacist with a invaluable 
refe renc e to be utilized as a 11 key 11 to clinical involvement wit h the 
m e dical staff. The printout may be incorporated into a patient's 
cumulative medication profile or merely used as a reference source 
to sc reen for probable drug-drug interactions. Another unique feature 
of the system i s that it reports important drug-drug interactions with 
each drug entity the pati e nt is receiving. The system is not limited 
iii 
( 
( 
t o the reporting of specific ihteractions which may oc c ur wi th the 
patient ' s current therapeutic regimen . 
Several illustrations are presented using the fi l e i n conjunc -
tion with a computerized medication profile system . T he applications 
of this system provide a rational approach to\vards determining the 
probability of drug-drug interactions resulting from the concurrent 
administration of drugs . 
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L INTHODUCTION 
( 
In the last several years there has been an increasing 
awareness of drug interactions in the medical an d pharmaceutical 
literature. The recognition of drugs that interact \.vith other drugs 
is of more than passing interest because of the potential consequences 
of unpredicted reactions. 
The phra se "drug inte r actions " is now part of the corn~mo n 
terminology us e d in medicine a nd pharmacy. The phenomenon of 
drug interactions includes the i::teraction of drugs with certain foods , 
laboratory tests, and various underlying pathological states. The 
scope of this proj e ct is r e stricted to drug-drug interactions. 
( Drug-drug intera ction is a phenon1enon which occurs -when 
the effects of one drug are altered by the prior or concurrent ad-
ministration of another (or the same ) drug (s) . It p resents a complex 
and profound problem. The means by which drug interactions occur 
are varied and complex. They may ar i se either from alteration of 
the abs o rption, distribution, biotransformation or excretion of one 
drug by anot her, or from a cor:nbination of the i r actions or effects. 
In order to have a general undc rstanding of drug interactions 
one must have a basic knowledge of a number of mechanisms. The 
basic causes for the se interactions are as follows : 
1. Potentiation 
Drugs having similar pharmacological properties can 
-1-
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be expected to potentiate one or more of the pharma-
( 
cological effects in patients taking these medications. 
2. Antagonism 
Drugs which have opposing pharmacological effects may 
produce a cornbined effect less than that of the active 
compound. The basic underlying mechanism of drug 
antagonism may be chemical, competitive, non-compet-
iti ve or physiological. 
3. Alteration of Gastrointestinal Absorption 
Drugs may alter gastrointestinal absorption by com-
plexation or be changing the pH of the gastric fluid. 
Since many drugs are weak acids or bases, the pH of 
, 
\ the gastrointestinal tract will influence the extent of 
absorption and (;llso the site at which absorption takes 
place. Drugs may form inactive or insoluble complexes 
with other drugs in the gastrointestinal tract. It is 
well known that t etracyclines can combine with di - and 
trivalent cations to form a complex which is poorly 
absorbed. 
4. Stimulation of Metaboli s m 
A number of drugs can increase the activity of liver 
microsomal enzymes. The enzyme stimulation results 
in a more rapid rnetabolism and excretion of other drugs 
( 
( 
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that are simultaneousiy administered. 
5. Inhibition of Metabolism 
Drugs that can inhibit the activity of liver enzymes in-
directly may increase the activity of drugs which depend 
on this enzyme for their metabolism. 
6. Displaceme nt of Drugs from Protein Binding Sites 
A competition will exist when two or more drugs are 
administered concurrently which are capable of binding 
to proteins. The drug that has the greater affinity for 
the binding site will displace the other from the plasma 
or tissue proteins. 
7. Interactions at the Receptor Site 
Some drugs combine with receptors to form complexes 
that elicit responses (agonists). Other drugs combine 
with receptors and elicit no responses (antagonists)"~ 
In this type of interaction the degree of response will 
depend on the drug and its affinity for the receptor site. 
8. Alteration of Electrolyte Levels 
Changes in electrolyte levels may make certain physio-
logical systems more sensitive to the effects of a partic-
ular drug. 
9. Alteration of Urinary Excretion 
Alteration of urinary excretion can be accomplished by 
-4-
chan ging the urinary pH or by interfering with tubular 
excretion. The renal tubular reabsorption of a drug 
can therefore be increased or decreased by another agent. 
The economic consequenc es of drug r eactions are staggering. 
It has been repo r ted that one seventh of all hospi ta l days are devoted 
to the care of drug toxicity, at an estim.ated yearly cost of three billion 
dollars (1). Considerable attention has been focused on the increasing 
incidence cf drug reactions. Approximately 18 to 30 pe rcent of all 
h ospitalized patients experience a drug reaction during their hospital-
ization (2). I n addition , 3 to 5 percent of all admissions to hospitajs 
are primarily due to an adverse drug reaction (2, 3) . 
It is a difficult and cumbersome task for a hospital pharma-
cist to accurate ly review all medication profiles on a routine basis 
for drug inte r a ctions . Hos pit.al pharmacists in the past ( 4, 5, 6) 
hc:i ve c1ttempted to rneet this challenge by developing charts and card 
fi les specifically designed for the rapid retrieval of drug interaction 
information. Hovvever, this is an e xtremely time cons uming task. 
Often it i s a retrospective review rat.hex· than a p rospe ctive analysis. 
This situation has created a growing interest as well as a potential 
need for more efficient elect ronic data processing (EDP) methods de-
signed for the retrieval and utilization of documented drug-drug inter-
actions. 
Another factor creating an interest in the field of drug inter -
\. 
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actions is the potential liabUity of the pharmacist and physician. 
The failu re to a void or notice a potentially harmful effect resulting 
from a drug-drug interaction can make either the physician or phar-
macist a candidate for liability. If screening a patient's m e dication 
profi le is a duty pharm.acists accept in a particular locale, then this 
will undoubtedly become part of the standard of care for patients in 
that area (7). When such is the standard of practice the public will 
expect the pharmacist to perform this function ca re fully and prudently . 
This project was undertaken to organize and develop a file of 
drug-drug interaction data suitable for computerization. In order to 
accomplish this objective severc1 l requirements were met. They are: 
1. Selection and evaluation of clinica lly significant drug-
( drug interactions from the scientific literature. 
2. Creation of a computerized data bank for drug-drug 
inte ractions . 
3. Design and developme nt of a computerized printout 
which reports the information in concise summaries. l The s cientific lit erature is replete with relevant clinical 
s tud ies (8, 9, 10, 11) and i solated case reports (12, 13, 14, 15 ) 
citing drug-drug interactions. The National Library of Medicine's 
computer-based Medical Literature Analysis and H.etrieval System 
(MEDLAR.S) compiles and produces Toxicity Bibliography which 
covers the adverse and toxic effects of drugs reported in approxi-
( 
( 
( 
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mately 2, 300 biomedical journals . This reference i s simila r t o 
other indexing and abstrar:ting servi ces in that they are all designe d 
t o pro vi.de a means to access the scientific lite rature p e rtai.nin g to 
chemica l and biological int e ractions. Services such as this are an 
important contribution towards realization of a comprehens ive toxi-
cology i nforrn;::J.tion system; however, they only constitute the initial 
phase in developing a mechanism which provides the clinician with 
drug-drug interaction data in a practical ' 1ready to us e " format. 
l\'1ultiple-drug administration i s common t o both hospitalized 
and am bulatory patients. It i s extremely common for a patient to 
be suffering from more than one unrelated disorder which demands 
simultaneous treatment with two or more drugs. In such instances 
in teractions are often un expected. Melman (1) reported that the 
ave ra ge patient in a ho:-::pital r e c eives six to ten drugs during his 
hospitalization. At this level of multiple-drug administration, the 
adverse reaction rate was reported to be 7 to 10 perce nt. Some 
patients receive more than 20 drugs s i multaneously. Under s uch 
circumstances the patient has at l east a 40 percent chance of ha ving 
adverse reactions to one or m ore of the drugs . Multiple-drug ther-
apy generally provides greate r efficacy than can b e achi eve d with 
full doses of s ingl e drugs, greater margin of safety, or more satis-
factory onset or duration of effect. In addition to the adrnini s tration 
of drugs concurrently for their independent and unrelated effect s , 
-7-
drugs are sometimes administered concurrently to make use of ex -
( pected interactions. The phcnothiazincs markedly affect the actions 
of a number of other drugs . Phenothiazines are often prescribed for 
thei r ability to poientiate the effects of central nervous system de -
pressants. It is common practice to administer a phenothiazine such 
as promethazine hydrochloride concurrently with a narcotic analgesic 
i n order to reduce the dosage of the narcotic that would normally be 
requi red to produce the desired level of analges ia. 
( 
II. METHODOLOGY ( 
The scientific literature, both primary and secondary ref-
erence sources, was reviewed and evaluated for clinical significant 
drug inte ractions. Only drug-drug interactiom reported in humans 
are included in this compilation. Drug interactions occuring only in 
animals or only in vitro systems have been excluded. 
EVALUATION PROCEDURE: 
In the assessment of drug interactions for this compilation a 
selected number of original references were reviewed and evaluated. 
Secondary references (eg. review articles, drug interaction tables, 
manuals, etc.) generally do not provide sufficient information on 
( which to make an evaluation. Secondary references are useful in 
cross-indexing closely related drugs but not, of the same group men-
tioned in the primary reference source. This is an extremely com-
plex problem since for every basic drug class (eg. barbiturates, 
corticosteroids, sulfonamides) there are many similar generic 
drugs which closely resemble the parent compound. In order for a 
drug interaction compilation to be of any practical value the structure 
activity relationships of these various compounds have to be taken 
into consideration. Secondary reference sources were first evaluated 
on the content of the discussion and the references they provided the 
user before any decision was made concerning the validity of a partic-
ular drug-drug interaction listed in the text. 
-8-
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The initi a l undertaking was t o review a number of abstract -
( 
i ng and indexing servi c es, whi ch included, Toxicity Bibliography, 
Interna ti ona lPharm_aceutical Abstracts, Clin-Alert, and FDA : 
Clinical Experience Abs t r acts . 
In the evaluation of the p r imary lite r ature for re ports of drug 
int e ractions the following journals were consulted whenever poss ible: 
1. Ameri can Journal of Psychi':1-_!!'Y 
2 Annc;. ls of Internal Medicine 
---- -- ---------
') 
0. Clinica l Pharmacology and Therapeutics 
----- -· --
4. British Journal of Anesthesia 
5. Britis h Med i cal Journa l 
6. Anes thes ia and A nalge :::.; ia 
( 
7. New England Jonrna J of Medici ne 
8. L a ncet 
9 . Neurology 
10. J ournal of P e diatrics 
Isolated case r e ports were only considered if there was some 
c onclusive documentation cited in the literature . Generally speak -
ing, it is extremely difficult if not impossible, to differentiate a 
case report of a suspected drug interaction from a idiosyncratic or 
hypersen0itive reaction attributab le to one of the active components 
in the multi-drug therapy . What further complicates a literature 
search for drug interactions is tha t the re are fe w accepted sci entific 
-10-
studies. The well-controlled clinical experiment is virtually non-
( 
existant for obvious reasons. It is difficult for a practitioner to 
j"ustify re-challenging a patient to a drug when a drug interaction is 
suspected. Especially if there arc other drugs or therapeutic meas-
ures available to treat the condition. When there v1as a choice of 
references a number of c riteria were used to C\'a luate the study. The 
general requirements for an adequately controlled study are an ob-
j ective crnd practical (s e nsitivity) method of evaluation, an adequate 
nurnbe r of subjects, lack of bias, concurrent comparison of the drug 
regimen in question with a referenc e standard, dosage varianc e , and 
appropriate statistical validation . 
( EVALUATION CRITERIA : 
There are many factors which may modify the effects of drugs. 
Some of these result in qualitative differences in the effects of a drug 
while others produce only quantitative changes in the effects of the 
drug which are dose dependent. It is extremely important to evalu-
ate a number of specific patient factors before an adverse response 
i s attributed to a drug-drug interaction. The physiological , patho-
logical and genetic factors which are well known to alter response to 
drugs and which were taken into consideration are age (infant and 
elderly), sex, race, body weight (nutrjtional state), tolerance , patho-. 
logical state, metabolic differenc:es and organ function. The specific 
mechanisrns for these physiological states altering drug response 
( are well documented in the literature (16, 17) . 
Another area of paramount importance is the variables 
associated with drug dosage and route and method of administration. 
Specifically these factors can be categorized as dosage, route of 
administration, dosage form, frequency of administration and dura-
tion of therapy. 
-11-
In any defined population, response to a drug generally follows 
a normal distribution. That is, a few patients will be hypersensitive 
and will respond to a small dose while a large majority will respond 
best in the therapeutic range. On the other hand, a few will be rela-
tively resistant to the effects of the drug. This kind of response 
curve applies to both therapeutic effects and adverse responses which 
may include drug-drug interactions. 
There are a number of parameters which proved helpful in 
determining the clinical importance of reported drug interactions. 
They are: occurrence (animal or human, in vivo vs. in vitro), in-
cidence, etiology, structural activity relationships, severity of re-
ported interaction, clinical manifestations, clinical course, prognosis 
and treatment. 
FORMAT AND INDEXING: 
This computerized drug interaction file is designed to be com-
patible with a number of existing computerized record keeping and 
drug information systems. The information in the file provides a 
( 
( 
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concise pharmacological summary i n a reporting format suitable for 
actual clinical use in the patient care envi ronment. 
The specific drug entities are cross-indexed to a message 
code . The mes s::ige code was assigned from a listing of valid nurn-
b ers calculated by (5A + 4B + 3C + 2D + E / 11 = Y x 1 1) . The source 
document (reference document ) which consis t s of the message codes, 
arranged sequentia lly, and the app r opriate dr ug interaction summary 
was then compiled. In the sourc e document the i nteractions enumer-
ated in the summa ry or message are coded to one or more specific 
refere nces. This particular coding system offe rs the us e r a means 
to obtain t he specific r eferences on which th e i nformation in the m e s-
sage i s based. 
Combi nation products in the top two-hundred prescribed drugs 
are included if one or more of the active ingredients was implicate d 
in a drug interaction. For example, Desbutal -15 Gradurnet which 
contains methamphetamine hydrochloride 15 mg. and pentobarbita l 
sodium 90 mg . i s ass igned t wo different messages. The messages 
for barbiturates and amphetamin~ s will be r e ported when the file is 
searched for possible drug-drug jnteractions involving this combina-
tion p roduct. 
III. HES ULTS AND DISCUSSION 
( 
The system is designed to provide the physician with impor-
tant drug information on selected drug-drug interactions. In addition, 
and equally as i mportant, it will provide the clinical pharmacist on 
the Patient Care Unit with a valuable reference to be utiliz e d as a 
"key'' to clinical in volvement with the medical staff. The basic ob-
jectivc of the system is to provide the physician and clinical pharma-
cist with a reference source enabling him to rapidly screen a medi-
cation profile for possible drug-drug interactions . When a probable 
drug-drug interaction is noted, and it i s definite ly determined the 
patient is receiving both medications concurrently the clinical phar-
( macist may then elect to contact the physician. In certain instances 
it may be only necessary for him to inform the nurse of the possible 
interaction. For example, if a patient is receiving both an antacid 
preparation and bisacodyl tablets, an enteric coated laxative, the 
pharmacist should a dvis e the nurse not to administer both medica-
tions simultaneously, but r ather as far apart as possible. 
A source document (refe rence document) was the first docu-
ment compiled (Appendix I). A five characte r nume r ic code was 
a ss igned to each rn.essage. The specific drug entities ·which were 
coded in the source document -vvere compiled and cross-indexed to 
the re spective message code (Appendix II). A second index (Appendix 
III) was compiled listing the message codes in sequence and the par-
( 
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( 
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ticular drugs to whi ch the summary applies . This index is useful 
to the us er when i t is necessary to determine the compl ete list of 
'drugs which have been indexed to any one particular message. The 
source clocurnent codes t he specific i nteraction enumerat ed i n t he 
summary to one or m ore specifi c references thereby offe ring the 
us er a means to obtain the r e fe rences on which the information i s 
based. A lis t of the selected references utilized is include d (Appen-
di ~~ IV). 
A p r intout of the messages exactly as they we re ret rieved 
from storage i s included for iJlustrati ve purposes (A ppe ndix V). The 
printout included in t h i s document r epresents a xeroxed copy of a 
computer printout which was photoreduced by twenty percent. 
The following message represents an example of a summary 
as i t was p rinted from the do.ta bank : 
Sah cylates elevate the anticoagulant response to oral anti -
coagulants , increase plasma levels of unbound penicillin G and de-
rivatives and potentiate methotrexate and s ulfonylureas. Salicylate 
plas ma l e vels may b e de c reased by corticosteroids . They n'lay de-
crease serum l e vels of i ndomethacin (Indo c i n) and inhibit uricosuric 
activity of sulfinpyrazone (Anturane ) and probenecid (Benemid ). 
If the information is of interes t to the physician hopefully he 
will be stimulated to s e ek the reference;:; and r e q ues t a " consultation " 
from the Pharmacy .for further evaluation. A pharmacy consultation 
would cons ist of a pharmacist reviewing a patient ' s m edical record 
in light of the drug-drug interaction information reported for a pa r-
ticular patient. The pharmacist would determine if the drug - drug 
( 
( 
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interaction information is s i gnificant in that patient and whether the 
patient 1 s physician should be informed of the findings . In order to 
.accomplish efficient retrieval of the specific references whi ch 
were applicable to the mes sage, a source document (reference docu-
ment ) was create d (Appendix I). Ideally it would be advantagious to 
create a file containing the hard copy of the references most fre-
quently requested. A s the number of references increase the original 
copy can be microfilmed a nd placed in a microfiche to reduce storage 
requ.iren1ents. The previous example appears in the source docu-
ment as: 
04383 Salicylates 
Sali cyla tes ele vate the anticoagulant response to oral anti-
coagulants (13), increase plasma levels of unbound penic illin G 
and de ri. vati ves (14) and pote nti a te methotrexate (16) and s ulfonylureas 
(17). Salicylate plasma levels may be decreas e d by corticosteroids 
(15). They may decrease se r um levels of indomethacin (Indocin) 
(53 ) and inhibit uricosuric act ivity of sulfinpyrazone (Anturane) (18) 
and probene cid (Benemid ) (J 9) . 
Generally speaking, the reference selected for the list (Appen-
dix IV) represent s the most sc i e ntific and significant literature cita-
tion r e viewed for that particuLi ,. inte raction. In certain instances 
two or more r e ferences are cited for a specific intera ction. When 
more than one rnechanisrn ha s be e n postulated in the literature a 
cross sarnple of references a re included. For example, salicylates 
have been shown to displace rnethotrexate from plasma protein bind-
ing, there by elevating plasma levels of free methotrexate. Howe ver , 1 
- 16-
salicylates rnay als o block the i 0 enal excretion of methotrexate. 
( 
Therefore the increased activity of methotrexate, usually manifested 
by increased toxicity, is attributable to both of these mechanisms. 
REPOHT ING FOH.1\/IAT : 
- ----·---·- ·---·--
The repol'ting format is designed io provide practical infor-
mation in a concise Sclmmary which can be easily understood and 
ut ilized in a patie nt care environment. The printout may be incor -
porated into a patient's cumulative medication profile or used strictly 
as a reference source to screen for drug-drug interactions . 
A reporting format (previously illustrated) was chosen which 
would enable a physician or a pharmacist to e ffectively re vi ew a 
( patient 1s previous medication history as ·well as the present drug 
therapy for suspected drug - drug interactions. A unique advantage 
of this system is that it reports important drug-drug interac tions 
with each dr ug entity the patient is receiving. The system i . not 
li m ited t o the reporting of specific interactions with the concomitant 
us e of two drugs . 
A retrospective review of a patient 1s previous medication 
history is a valuable exercise in light of the extended biological half-
life of many drugs and the many structural similarites which exist . 
This is extremely important s ince so many of the reported drug in-
teractions exhibit structure activity relat ion s hip s 'and are not specific 
for any one drug entity. The sulfonamides are a class of drugs in 
-17-
which a number of the drug interactions invol ving t hese compounds 
( are structure dependent. This informat ion is of practical value in 
a patient c a re e nvironme nt, b ecause it pro vid e s the physician with 
d rug inte r action i n fo rrnation which will enable him to make an intel-
lige nt choice as to the appropriate class of drugs to p res cribe. 
This sort of information is also helpful in predict.tn g unknown 
r eactions which may occur with new drugs . The r e are niany ins t ances 
when it is impossible to pre di ct a p os sible drug - dr ug inte r a ction based 
on the st ructure acti vity r e lationship to a parent compound. For ex -
ample , a new drug with a phenothiazine nucle us would be expected to 
potentiate t he effects of central ne rvous system depressants. In the 
majority of instances so -calle d new drugs are m erely mol e cular 
( modifications of an existing ge ne ric drug or are compound s which are 
t ransformed to a pharmacologi ca lly a c tive compound which in itself 
i s comme rc ially available. 
The importance of knowing b eforehand whe n two drugs given 
together will result in an interaction cannot b e ove remphasized. 
Since drug interact ions unknown t o - date c a nnot be predicted in patients 
taking two or more drugs at the same time , only those interactions 
already repo rted i n the lite rature offe r any clue as to what d r ugs 
make a rational combination. 
"' 
LITERATUR.E EVALUATION : 
( Drugs which exert a similar pha r macological a_cti on and which 
( 
( 
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are prescribed for the sarn_e therape utic purposes were not con-
sidered as e xamples of drug-drug interactions having additive or 
synergistic pharmacological effects (e.g. epinephrine and levarte re-
1101). Another broad area which was not included in this fil e is the 
rationale of combining both bacteriostatic and bactericidal antibiotics 
in the same therapeutic regimen. Jawetz (18) has reported that anti-
biotic antagonism may oc cur but the net effect plays a minor role in 
ch nical medic:ine . Thi s has been an extremely controversial subject 
for years and still has not been r esolve d. The inclusion of this sort 
of rna terial in a d n 1g inte r action compilation is of no practical value. 
One of the majo r difficulties in evaluating drug interactions 
is, the occurrence of contradictory reports concerning a specific 
interaction. For example, a drug interaction of considerable in-
teres t to neurologists is the reported inhibition of diphenylhydantoin 
and phenobarbital metabolism by m ethylphenidate. R.eccnt studies 
(19, 20) indicate that d uring the p eriod of concurrent drug adminis-
tration there is no elevation in diphenylhydantoin plasma l evels or 
clinica l s igns of d rug tox icity . Based on the results of these two 
studies this suspected interaction was not included in the file. Al-
thou gh these studies do not preclude the pos sibility of an interaction 
of methylphenidate with the anticonvulsants they do suggest that if 
this interaction does exist it m ust occur infre quently. 
A similar case is iJlustrated by the combination of a tricyclic 
( 
( 
( 
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antidepressant and a n1onoamine oxidase inhibitor (MAOI) in the 
treatment of depression. This combination is often contraindicated 
ii1 the literature as wdl as the respective product brochure. In 
certain instances a medication-free period of two weeks i s recom-
mended after discontinua nce of the MAOI and the institution of a tri-
cyclic antidepressant. However, there have been t w o recent publica-
tions (21, 22) concerning antidepressant therapy which i ndicat e t hat 
t he cornbined use of a tricyclic antidepressant and a MAOI may not 
be hazardous and that this method of treatment may be used wi th 
cons iderable benefit to th e patient. Since it was listed as a caution 
in the product brochure it was decided to include it in the files des-
pite the fact that the clinical significance of this inte raction has not 
been demonstrated. 
The interaction between chloral hydrate and warfarin sodium 
i s even more complex. In 1966 Cucinall et al (23) suggested that the 
coadministration of bishydroxycoumarin and chloral hydrate resulted 
in a reduction in expected plasma levels of the anticoagulant with a 
decrease in prothrombin time. Se llers and Koch-Weser (24) showed 
that the administration of 1 Gm. chloral hydrate for one week in-
c reased the nypoprothrombjnemic effect of warfarin sodium by 40 to 
BO percent. Griner, P. F. , et al (25} recently conducted a study to 
determine the effect of chloral hydrate in patients receiving long-
term t herapy with warfa rin sodium. Their findings, unbelievable as 
( 
( 
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they may seem, indicated that chloral hydrate or its equivalent as 
chloral b etai ne , in doses of 0. 5 to 1 Gm. daily, did not influence the 
·anticoagulant effect of warfarin in such patients. Since the studies 
reported in the literature are not conclusive and the results remain 
contradictory it was decide d to i nclude in the file a statement to the 
effect that 11 chloral hydrate varia bly effects the anticoagulant response 
to oral anticoagulants. 1 1 This statement merely points out the fact 
that chloral hydrate may in some way interfere with the hypopro-
thrombinemic effect of oral anticoagulants. 
Diphenylhyda ntoin is one of m any drugs metabolized by enzymes 
found in the m icros omal fraction of he patic cells. The drug pheno-
barbita l, is known to stimulate these enzymes and thus the metabolism 
of diphenylhydantoin. Apparently, the ability of phenobarbital to lower 
plasma levels of diphenylhydantoin is not so great as to offset its own 
anti convuls ant activity. Although a biocheniical antagoni s m e xists 
the net result is a potentiation of the desired pharmacological effects. 
This particular combination is the drug re gi men of choice for grand 
mal epilepsy. A suspected or reported drug• interacti on can not be 
evaluated solely on t he b as is of biochemical data. It mu st be remem -
bered that combination drug therapy attempts to achieve one or more 
therapeutic effects with a n1inirnum of adverse e ffe cts. The ultimate 
clinical obj ective of the therapeutic regimen must always be cons idered. 
On the other hand, this antagonism may be significant if the patient 
( 
( 
was receiving large doses of diphcnylhydantoin (common to hospi-
talize d patients in psychiatric hospitals) and then had the phenobar-
bita l disconti nued. In this particular case, the diphenylhydantoi n 
plasma levels may well ri s e to a toxic level. 
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Isolate d cas e reports (one or two patient s) were excluded ex-
c e pt the reports concerning methotrex ate and small pox vaccination. 
Mc thotrexate , a 8 ntineoplastic agent, may inhibit the imm~nological 
r esp onse to s mallpox va ccine resulting in generalized vaccinia. The 
decisi on to include this interaction was strictly subjective and not 
bas e d on any rational scientific data. Regardle ss of the severity of 
the reaction one woul d not e xpect to find numerous cases or c ontrol-
led s t udi e s s ince the use of this combination is very limited. An 
important cons i deration is that by r eporting th is intera ction it may 
ale rt the prescribe r to possible difficulties with othe r immunosup-
ressi ve drugs , namely the corticosteroids. 
There are a number of interactions which are well known in 
medical ci r cle s but spe c ific clinical documentation is lacking . The 
major area of concern to the clinician is that although the clinical 
data is l acking the y are included in the pharmace utica l brochure 
whi c h brin gs a bout a potential lega l liability. From a medicolegal 
sta ndpoint it is wise to includ e these in a drug interaction file in 
orde r that the' physician will be fore wa r ne d about a pos sible adve rse 
effe ct. If the drug intera ction is included in the product literature 
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as a c a ution or wa rning t h e physician is faced with a legal dilernma . 
( In this situation the phys ician may wi s h to select a nothe r drug or 
decide to run the ri sk to the patient . This situation i s applicable 
to the following examples of d rug-d rug interactions: Propoxyphene-
orphenadrine , meperidine - is oniazid, a nd allopurinol -i ron. 
CUH.R E NT l\PPLICA T IONS : 
-----------·-------
The system is designed in a manner which enables it to be 
i nco rporated into a prog r am using comp uterized medication profiles. 
The messages or supple m entary notes pertaining to possible drug -
drug interactions i mmediately foll ow the cumulative medication pro-
file (Illus t ration I). In the first example (Illustration I) the inform a-
( ti on pres e nte d in the accompanying m e s sages does not suggest any 
specific drug int e r actions with the drug regimen outlined in t he m e d-
ication profile. However, the information would be extremely us eful 
to the phys ician if he were considering adding additional drugs to the 
prese nt therapeutic regime n . The i nformation p re viously presented 
m ay forewar n hirn of an intera ction. In the second example (Illus-
tration II) the messages describe pertinent drug-drug interactions 
which are possible with the curre nt therapeutic regimen. If a med-
i cation has bee n discontinued the drug interaction summary is not 
printe d. This check i s built into the computer program. For ex-
ample, in Illus tration I the m essage summary for diphenh ydramine 
( hydrochloride (an antihistamine) was printed while it was not in the 
( 
( 
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second illustration since the drug had been discontinued. 
The program of instructions designed to print the cumula-
tive medication profile and search the drug interaction file for the 
appropriate drug interacbon rnessage code is included (Appendix VI). 
The cornputer program is written in COBAL. 
From a practical viewpoint it is difficult to justify a compu-
ter program which does not always produce a tangible result. It is 
much n1ore difficult to implement a program limited to professional 
objectives as opposed to a cost accounting program designed to pro-
cess medication charges . As with most organizations computer 
time is expensive and is limited. An additional feature of the cumu-
lative patient medication profile described in this project is that it 
can be used as a dispens ing reco i·d for a medication distribution 
system. 
All that is necessary to incorporate this file into an ongoing 
com p uterized system is to place the file in stora ge and then assign 
message codes to drug names listed in a computerized drug product 
file or a drug data file . In order to facilitate this task the specific 
generic entities are cross-indexed to the appropriate message codes 
(Appendix II). The drug product file can be compiled by the individ-
ual institution or a commercially available file can be purchased. 
The American Society of Hospital P harmacists Drug Product Informa-
tion File (DPIF ) serves as a master drug code dictionary and is adapt-
( 
( 
( 
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able to each individual system . The DPIF is a data bank composed 
of terms and code numbers for commer cially available drug products 
\vhich is organized to facilitate automated processing of dn1g data . 
This particular multi~fun ctional drug coding system is b ased on a 
5-digit generic drug product numb e r that completely identifie s the 
generic drug product . 
R.etrieval may be accomplished by one of two bas ic rnethods: 
(1) As a n integr :1l component of a computerized medication profile 
and I or pricing system. (2) Manual selection of pre-punche d cards . 
The file can be eas ily utilized by individua ls who do not have 
a computeri7-ed profile system. They can create a tub f ile of pre-
punche d index cards and then sele ct the applicable cards upon special 
req ue s t. A prospe ctive re view of drug interact ions ca1i. then b e con-
ducted by running a program to search the file in storage . A system 
simila r to tbis is utilized by the Drug Information Center, Mercy 
HospitaJ, Pitts Liurgh , Pennsylvania (2 5 ). 
FUTUHE APPLICATIONS: 
It is possible to prepare a manual from the drug-drug inter-
action file. This aspect of the system would be especially useful to 
individuals without access to electronic data processing facilities. 
This would serve as a supplementary reference source which would 
enable the user to rapidly screen a medication profile in lieu of a 
computerized system. Under certain circumstances a request for 
( 
( 
( 
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an immedia,~ e computer search is impractical, e.g . servicing a 
drug informati on reque st VIA the telephone or while participating 
·in work and teaching rounds. The major sections, nam e ly, the 
Source Document, Indexes , and Selected References can be cross-
indexed, typed and then photoreduced . 
Another valuable application of this file is that a drug-induced 
l aboratory test interference file can be used in conjunction 1,vith the 
pre sent system or incorporated into it. Drugs n1ay possess the 
inherent ability to alter laboratory test values through a variety of 
pharmacologica l , physica l or chemical mechanisms (27). A drug 
may affect the normal phys iological levels of the particular sub-
stance being measured. Through physical or chemical interference, 
a drug may not only alter a test 1 s value but may prevent its deter-
mination by a particular method. The extended biological half-life 
of drugs as well as inte rmediate or end products of drug metabolism 
may often be respons ible for unsuspected alteration in l a boratory 
test values. The reporting format and retrieval system is compat-
ible with a progra m conducted by the P athology De partment of 
the Rhode Island Hospital, Providence, Rhode Island (28) for report-
i ng possible drug-induced modifications of laboratory test values . 
In this particular program a computerized cumulative report of a ll 
laboratory test s is prepared for every patient who had a test conduct-
ed. Imn1ediately following the cmnulative report are supplementary 
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notes pertaining to d rug -induced laboratory interferences for 
( the tests outlined in the report. Although it is ideal to include this 
_inforrnation in a cumulative laboratory report there are instances 
when this may not be practical and it would be preferable to in-
elude this information in the medication profile. A p r i me exampl e 
would be a s ituation where a patient obtains health care services 
from an arnbulatory patient care facil ity. Usually after the i nit ial 
batte ry of laboratory te s t s only a fe ·w tests, if any, are conducted 
for continue d surve illance of a particuJa r phys iological parameter. 
In this situati on , it w o uld not be economi cally fea s ible to run a 
specific program for laboratory tests. 
The fi l e is compatible with existing compute rized drug infor-
mation services. Another advantage of this type of drug-drug 
inte raction file i s that it s use is not limited to an institutional setting. 
The system may be incorporated into a computerized drug informa-
tion se rvice c oordinated by a r egional drug information network 
and offered to community practitioners on a subscription bas i s VIA 
on-line compute r t erminals. 
j 
( 
ILL UST RATION I 
Patient Medication Profile. Example I 
( 
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MUO ERN HCSPI 1AL 
Ol PARlfJE Nl OF PHARMACY 
CUVLLATI VE Ml UlC AT I GN PRlFI LE FOR KA REN SMITH 
I 
NO. 6572 8 1C ROCfJ 6C2 AGE 26 
Sl AP.T ST OP MEC ICATIC N ORDERED PHYSICIAN 
2/C S OIAZ~PAP 5 ~G . PO TIO PC 
2 / C<l LITHI UM CA RBON AT E Q. 3 GM. PO TI O PC CM1PBE LL 
lSOCARBOXAZlO 10 ~G . PG TIO 
? /1 0 SULFI~OXAZ D L E 0.5 G~. PO TIO STE INBEHG 
2/l. l DIPHENHYD~ AH INE HCL 5C MG. PO HS PRN C Al«PC ELL 
2 /11 ME TA HUCIL 5 GM. PO TID 
2111 2/llt BETHAHCHG L CHLCR !DE lC l"G . PO 1 I C 
END OF PRCFI LE l/17 /7 2 
( 
( 
\ 
( 
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PROd AB LE CRUG-DRUG INTERACflONS FCR KAREN S~llH NO. 657i.'.UlJ 
LI THlL~ EXCRETIU~ I S INCRlASlG av A~lNOPH YLLINE, SLDIU" BICARBONATE AND 
LA RGE 1JCSES Cf SOU!LM CHUlt<IlJf.. LC\i SC1DIUI" 1Nl/lKE 11.AY PRECIPI rATE LITHIUM 
TCX ICll V. 
HUl '•JAMIN~ OX I OAS[ INbl ll !TO~ S PCTENT l ATE THE PHAR~ACOLOGJCAL EFFECTS CF 
AMPHL l '1'1INES, Mf:rHYLPl-'ENHJ,HE ( , '.lTAU:~ ), H.lCYC LlC MH IG ' : :;;·u:S Sfd\TS, hYPC-
GLYCE ~ ICS A~[ SY~PATHDMIMET J C~ 5UCH AS EPriEOk!NE, M[TA~A~I~U l ( AKAKI~EI, 
PHEhYl.EPHRl~E A~C P~E~YLPRUPA~OLAM I NE . CC~COM!lANT us~ WI TH ~EPERIOlNL OR 
LEV COGPA I NCMEASES l NC l CENCE or ACVtR~E EFFECTS. 
SULH1NAMIL' LS fJ,/,y PGlENT!ATr fHE f-' YFGGL Y.:.E MIC RESPUNSE TO Q;{t'\ L HYPO-
GLYC EMICS ANC HE:V1\T[ srnu:~ LC'/i. LS OF fJ,ETHCTR[XATE. CC' lCO;JJT/d\ f US[ l·ilTH 
µElHE~A~INE CUMPOUNCS FREWUENlLY t< ES ULTS J~ CRYSTALLUR[A AND THE F OK~ATION 
or A P"l:Cil'IL\~E. 
ANT!hISTA~lNES Pf\ Y PRODUCE f\CU ITIVE CN S DEP RESSANT EFFEC TS WHEN USED 
(Q,\((JfJ!TA i,J lLY UHi ETHYL ALCOHOL, BARll lTU "1\ 1ES M;lJ PHf:~OTHI/.1lii~ES . TH[Y 
1 1 .~ Y POTE:~ TIAH TH: Pl-<Af<l"ACLJLOG'ICAL ACTI\tITY OF At\TlCHOLlNEl<GICS Afl:D THE 
A[VERSE EF~CC1S GF TRICYCLIC AHTIDEPRESSANTS. 
FOR fLRTHrn li~rORMAT I01 Cflll CHUG l NFCH11 AT!ON Cl:tvTER EXT 1234 
( 
ILLUSTHATION II 
Patient Medication Profile. Example II 
( 
-3 0 -
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MOllt:RN HOSP IT .-'> L 
DcPA~ T~E NT UF PHARMACY 
CUHLLATIVE MEOICA T IG~ PRCF ILE FCR RGBEkT E. J CHNSON 
NO . J363fJ20 ROCM 7 23 hCE 1 a 
Sl M<T STOP l\lLJCATlC1 Ci1-UL1u:o PHYS I CIAN 
2 1 02 2/03 UlGOXlN 0 .2 5 VG. PO TIO RIL EY 
2 10 2 2/ 02 BTSACODYL 5 ~G. PO BID VIN CE NT 
l/03 2 / UJ EISAC00Y L LO MG . R VI NCEN T 
/' / lH CASTOR CJL 30 ML. PC VI NCtN T 
210 .~ OIGOX IN 0 . 25 ~ G . PC QU RIL EY 
2 / 03 2 / 03 ~ENTOOA~ E !TA L sca1u~ 100 ~G . PO HS VINCENT 
2 I O·'i 2 / 04 DI GOXIN 0.25 ~ G . IK VI NCEN T 
2 I C4 2/04 ATROPTNt SUL~ AT E 0.4 PG. IM PRE-CP VI NCENT 
2/ 04 2/ 04 MEPER !DI NE HYDRGC HL CR ID E 50 MG . I M PRE-OP V 11\CENT 
2 / C4 2/04 PROMElHAZ I NE HYDRCChLCR!ilE 25 MG . l M PKE-C P V li'1CENT ( 2 / C4 2 / C5 ~EPEk ID! NE HYO RCCH LC RIDE 100 MG . l~ Q 4H P~~ RILE Y 
2 1 4 2 / 06 PGTASS IL M ChLJ RIOE 40 HtQ. I V I N 05~ 500 ~L . VI ~CENT 
2/ 04 2 / 06 ~LLTIVITA klNS 10 ~L. IV I N U5H 10 00 ML. VI NCEN T 
2 / C5 2/ 11 kt TAM LCIL 5 GM . PC e1c RIL EY 
2/C5 2 / 07 PENICILL IN G POTASSIUM 1, 000,00C ~~ITS IV Q 6h RILEY 
2/05 2 / 06 VE PE RID I NE HYO RCCH LCRIDE 50 VG . I M Q 4H PRN VINCE NT 
2 / 06 2 / 0H PE~TAZOCINE 30 MG. I M Q 4H PRN V H;C EN T 
2/07 2/11 AM PIC I LLI ~ 0 . 5 GM. IV Q 6H RILEY 
2/ C7 2 / 08 T R lMETHOBEN Z A~ l OE HCL C.2 GK . R Q 6H PR N HCLL ONO 
2 / 01.l 2 /11 PKCCHLORPERAZINE ~ALE A T E 10 HG . I ~ Q 6H PRN VINCE !'.T 
2110 2/1 5 MA ALOX 30 VL. PC CIU HIL EY 
2/U 2 /1 3 CHL URD I AlE PO XIDE HYDKCCHLOR I DE 10 MG . PO TIO fUL EY 
C ONTI~UED ON NEX T PACE 
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l<C:flfkT E:. JONSllN ND• E363b20 RCCi"• 723 PflGI: 2 
2 /11 211 ':> GEN TM1 ICII\' SULFtH E 40 MG. Q 12H CUfTS 
2111 2/11 LI COCA I N!:: HY lJ:WCHLOI< I DE 2 GM. IN C5 1-J lOOU ML . CUTTS 
2 /11 2/l l F-LR 1. 1SEM IDE 40 (f:G . IV cuns 
2/11 2 / 11 SCC JU.1'1 BICA RDONA TE ':>O PCT, 150 n IV CUTTS 
~ / ll 2111 MAGNI: S IU'. SULFA H' 10 PCT, 10 ML IV CUTTS 
2111 2/12 n YD RG COR IIS L!t-;£' SC CI L M SLCCil\ATE lOC MG. IV C:6H CUTTS 
21 lJ 2111 ~il: l ARAi-11 ~\ CL 10 t'G. lV CUTTS 
2 111 2 /1 1 METHYLPRECNlS ULON E sno . SUC ClllATE 0. 5 GM. IV cuns 
2 / l l 2/ 11 FUfWSEMID t' 200 MG. IV CUTTS 
2111 PO TASSIG M ChLORlDE SYRUP 25 MEQ . PC TIO KILEY 
2 /1 1 2 /1 5 !-'llkfJS E ~:IOE 40 MG. PO CD CUTTS 
2/12 2 1 11. NcCSP ORIN GU IRRIGANT VI NCE NT 
2/ lZ 2/16 CHHALOTH I N SCDilii" 2 GM. IV Q 6H RiU: Y 
2 /13 2115 hfPA l\ lN SCDJ U~: 100 0 Uf\ ITS IV Q 6H V INCE NT 
( 21 lit 2/15 OIPHt:NH YlJHAMINE HCL 50 t1 G. PO HS PRN RIL EY 
2/16 PHENOS ARB I Tl\L 32 l'G . - FO CID RIL FY 
211 6 U ;L OH AL HYD R/\ TE 0.5 GM. PO HS RI L EY 
2/16 wfll{fAH l i\ SO UIUM l c l'G . P O QD RILEY 
Ei\D OF PRCFI LE 2 /l"l/7 2 
( 
( 
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PROHA~LC LRUG-CRUG !NTE ~A CTI CN S roR ROBERT E. J OHNSCN NO. 8363820 
CIGIT~LIS GLYCGSIUES Aki: P~ArtACCLUGlC~LLY PGTE NTI ATl:O [Y PA RE~TERAL 
CALC!U i·1 p;;;::p;·.iu~f{ l ;t;s J\i~O DIURcl l(.S FHCL;UCTl,G POTASSlUc M;O FAGl~ES IL 1·1 
Ol:FICI~NCfFS . A~PHC T ERIC I~ B IFUNGIZCNEl ~AY PRC.DUCE HYPG~ALEPIA 
P ~~f:C1f'lTAl l1«l: LJ1Gli/\LIS TO>:iC.llY. SYMPAH!OM J METlCS ~'i\Y lNC1.:E.JlSE rnCICl:N CE 
OF CA RDIAC A~khYThMiAS . 
B/\RCIUktTES- ACDJTfVE LFFECTS HAY eE SEEN WITH TrlE CUNCO~l T ANT USE Gf 
ANT1 H tSIA Mil\ES 7 P!:rNfflf-'IAlINES t.'<L ClH ER (;\$ OLPRl:SSA!'!TS. THEY MAY 131: 
PCTE NTI•TEC tY PRGCARP/\Z!NI: l ~ATLLA~EI. TH fY ~AY OECk~AS~ THERAPlUTIC 
EFFCCTS ff OR1\L ANT JCCAGULAidS, rnrcvruc Ai'JTlCFPRf:SS ,\N TS AND Gl\lSEC-
t liLVJ~l. H!L\' i-11\Y Vt.RI/ulLY f:FF[CT '.OERUr'. U1PhEt• YU-YDA!\TCI~. LEVELS. 
CHLO RAL liYDKATI: VARIABLY l:FFECTS THE ANTICCAGULANT RESPCNSE TO ORAL 
A I\ T 1 CO {J(; UL A 1, TS. 
O~AL A~TJCCAGULANTS AR~ POTEl\ TI ATEO BY A C E T A~ INOPHE~, ESTRCGENS, 
'" 'lf'Ul. lC Sf[:::o1us, CHLURAMPrif.NICOL , CHOLl:STY:-{/l f-\ !1,E IC U~'.FlDl , · CLOFIERATE 
( AlRO MID SJ, D - THY~LXIN~, Phfl\YLBLTAZJl\E ( 8U TAZC LI OIN l ANC PHENYRAMiDOL 
I ANA LEXINJ . l H~Y NA\' tit POTENTI Af [D BY A~l\UGLYCCSICE Al\TIB!OlJCS, ur-
PHEl\YLHYilANT[ll\, INCO~E THACIN, ~LlNlDil\E A~O SAllCYLAfE~. THEY ARI: A~TAG­
ONIZEL BY ET~YL ALC rHOL, DARB ITU~A TlS, ETH CHLCR VYNOL, G~ISEGFLLVI N ANO 
GLUlEll l l ~ IDE. THEY /~~ ~AKIABLY AF FECTED BY CHLC.RAL HYDRATE. 
FO R FLRTHER INF ORM ATION CALL CRLG I NFOR~A TI C~ CENTER EXT 1234 
( 
IV. CONCLUSIONS 
The design of this computeri zed drug-drug inte r action 
fi le offers several unique features . 
1 . The program re ports important drug-drug interactions with 
each drug entity the patient i s receiving. The system i s 
not lirnited to the reporting of spe cific interactions which 
may occur with the patient ' s current therapeutic regimen. 
2. The reporting format is designed to provide practical i nfor-
mation in a concise s ummary which can b e easily under -
stood and utilized in a ny patie nt care environment. 
3. The printout may be incorporated into a patient's m e dical 
record or us ed strictly as a referenc e source to screen for 
drug-dr ug interactions. 
4 . The file is compati ble with existing computerized medica-
ti on profiles and record systems as well as c omputerized 
drug information services. 
5 . The use of the drug-drug interaction file i s not ljmite d to 
a hospita l or a comprehensive ambulatory patient care 
facility. The system may be incorporated into a comput-
erized drug information service coordi nated by a regional 
drug inform.ation nehvork and offered to community pract-
itione r s on a subscription basis. 
-34-
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6. The various components of the system can b e assembled 
in a manner which would create a cross- idexed manual of 
hum.an drug-drug interactions. This aspect of the system 
would be espe cially useful to individuals without access to 
electronic data processing facilities. 
7. As an added feature the c u mulative patient medication pro-
file can be used as a di s p ensing record for a m edication 
distributio n system. 
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APPENDIX I 
Source Document 
· 00086 Acetaminophen 
Acetaminophen elevates the anticoagulant response to 
oral anticoagulants. (3, 4) 
00124 Acetazolamide 
Acetazolamide (Diamox ), urinary alkalinizing agent, ela -
vates serum l evels of amphetamines (42), tricyclic antide-
pressants (33, 37) and quinidine (78) by enhancing renal reab-
sorption. It may antagonize the activity of methenamine com -
pounds. (79} 
001 67 Alcohol, Ethyl 
Ethyl alcohol-additive effect s may be seen with CNS de pres-
sants (26, 54) and antihistamines (26). It may antagonize the 
pharmac ological effects of the oral anticoagulants {28) and 
diphenylhydantoin (104). It may enhance the adverse effects of 
guanethidine (29 ), nitro glycerin (27), disulfiram (Antabuse ) (30), 
metronidazole (Flagyl) (31} and tricyclic antidepressants (21). 
It prolongs the action of insulin. (129) 
00205 Allopurinol 
Allopurinol potentiates the effects of bishydroxycoumarin 
(10), and mercaptopurine (11, 58). It may increase h epatic 
-40-
-41-
iron concentration. (140) 
( 00 2 99 Antacids 
Antacids containing divalent and trivalent cations decrease 
oral absorption of tetracyclines. Antacids should not be ad-
ministered simultaneously with enteric coated products. (6) 
Sodium polystyrene resin (Kayexalate) binds magnesium and 
calcium ions found in antacids resulting in systemic alkalosis. 
(17 6) 
003 3 7 Amantadine ___ " ________ _
Amantadine (Symmetrel) potentiates the pharmacological 
effects produced by l evodopa. (9) 
Aminophyllin may impair the therapeutic response to lithium 
carbonate by increasing the renal excretion of lithium ions. (80) 
00 515 Aminos a licylic Acid 
Aminosalicylic acid plasma levels are elevated by probene-
cid (Benemid). (81) 
00566 Ammonium chloride 
Ammonium chloride (urinary acidifier) may decrease renal 
reabsorption of amphetamines {42) and tricylic antidepressants 
(33, 37 ). 
00604 Amphotericin B 
Arnphotericin B (Fungi.zone) may produce hypokalemia 
( 
( 
precipitating digitalis toxicity. (82) It may potentiai:e 
neuromuscular blockade of skeletal muscle relaxants. (82) 
00647 Ampicillin 
Ampicillin plasma levels are increased by concomitant use 
of probenecid (Benemid). (43, 56) 
00698 Amphetamines 
Amphetamines potentiate MAOI (20) and antagonize the 
effects of guanethidine (40 ). Phenothiazines may antagonize 
the central effects of amphetamines (41). Urine acidifying 
agents decrease renal reabsorption and urinary alkalinizers 
-42-
such as acetazolamide (Diamox), sodium bicarbonate and thiazide 
diuretics increase reabsorption. (42 ) 
00744 Angiote nsin Amide 
Angiotensin amide (Hypertensin)-induced a ntidiuresis and 
antinatriuresis is reversed by ethacrynic acid (Edecrin) and 
furosemide (La six). ( 44) 
007 52 Anabolic Steroids 
Anabolic steroids may potentiate the activity of oral anti-
coagulants (63), phenylbutazone (Butazolidin) and oxyphen-
butazone (Tandearil) (155, 156) They may decrease insulin 
requirements in diabetics. (188) 
00'7 87 Anticholinergic Drugs 
Anticholinergic drug s may potentiate quinidine (83) and the 
-43-
secondary pharmacological effects of antihistamines and 
( tricyclic antidepressants. Proprano.lo.l (Inderal}-induced 
. adverse effects are antagonized by anticho.linergics. (84) 
They may pr oduce extrapyramida.l symptoms when used simul-
t aneous.ly with rnethotrimeprazine (Levoprome). {149) 
SJ0.§_~5 Antic<?~_gu.lants, Oral 
Oral anticoagulants are potentiated by acetaminophen (3, 4} 
estrogens (98), anabolic steroids (63), chloramphenicol (64), 
cho.lestyramine (Cuemid) (68), clofibrate (Atromid S} (63), 
Phenylbutazone (Butazo.lidin) (28, 39) and phenyramidol (Ana-
lexin) (72). They may be potentiated by aminoglycoside anti-
biotic s (64), diphenylhydantoin (69 }, indomethacin (71 ), 
( quinidine (28, 185) and salicylates (13). They are antagonized 
by ethyl alcohol (28), barbiturates (49), ethchlorvynol (11 7), 
griseofulvin (28, 72) and glutethirnide (49, 70). They are vari-
ably affected by chloral hydrate (38, 65, 66). 
Tricyclic antidepressants may potentiate the adverse 
effects of MAOI (21) and ethyl alcohol (21, 59) and the phar-
macological effects of sympathomimetics (36), thyroid prepa-
rations (35}, antihistamines and anticholinergics. They may 
antagonize guanethidine (60, 61, 62). Barbiturates appear to 
"' 
decrease therapeutic activity. (38) They are potentiated by 
( 
( 
methylphenidate. (34) Urine acidifying agents decrease renal 
reabsorption and urine alkalinizing agents increase reabsorp-
tion . (33, 37) 
0088 4 Antihistamines 
Antihistamines may produce additive CNS depressant ef-
fects when us e d concomitantly with ethyl alcohol (26), barbi-
turates (55) and phenothiazines (157). They may potentiate the 
pharmacological activity of anticholinergics and the adverse 
effects of tricyclic antidepressants. 
00892 Antihypertensive Agent~ 
-44-
Antihypertensive agents may be potentiated by methotrimep -
r azine (Levoprome) (149), procainarn.ide (Pronestyl) (125 , 168) 
and propranolol (Inderal) (84, 126 ). 
00914 Ascorbic Acid 
Ascorbic acid {urinary acidifier) may antagonize ampheta-
mines (42) and tricyclic antidepressants (33, 37). 
00957 Barbiturates 
Ba rbiturates-additive effects may be seen with the concomi-
tant use of antihistarnines, phenothiazines and other CNS depres-
sants . (55} They may be potentiated by procarbazine {Matulane ) 
(48). They may decrease therapeutic effects of oral anticoagu-
lants (49), tricyclic antidepressants (38) and griseofulvin (37). 
( 
They may variably effect serum diphenylhydantoin levels. 
(45, 46) 
01058 Bishydroxycoumarin 
Bishydroxycoumarin may potentiate the sulfonylureas 
-45-
and increase serum l evels of diphenylhydantoin (50). It is 
potentiated by acetaminophen (3, 4), estrogens (98}, anabolic 
steroids (63), chloramphenicol (6 4), cholestyramine (Cue mid) 
(6 8), clofibrate (Atromi.d S) {63), d-thyroxi.ne (63), phenyl-
butazone (Butazolidin) (28, 39) and phenyramidol (Ana l exin) (72). 
It may be potenti a ted by aminoglycoside antibiotics (64), diphe -
nylhydantoin (69), indomethaci.n (71) and salicylates {13). It is 
antagonized by e thyl alcohol {28), ba rbiturate s {49), ethchlor-
vynol (117), griseofulvin (28, 73) and glutethimide (49, 70). It 
is va riably affected by chloral hydrate. (38, 65, 66) 
010 90 Bisacodyl 
Bisacodyl (Dulcolax ) tablets should not be taken concomitant-
ly with antacids. (18 2) 
011 3 9 Calcium. Prepa rations (Parenteral) 
Calcium ions administered parenterally may pharmacologi-
cally potentiate digitali s glycosides. (74, 75) 
011 4 7 Carbenicillin 
Carbe nicillin (Pyopen, Geope n) plasma l evels may be eleva-
ted and prolonge d by probenecid {Benemid) (186, 187) 
-46-
011 71 Cephalosporins 
( Cephalosporins, all-plasma levels are elevated by 
probenec id (Benemid) (43, 76). Concomitant administration 
of colistin increases incidence of nephrotoxicity. (96) 
01236 Chloral Betaine 
Chloral betaine (Beta - Chlor) variably effects the anti co-
agulant response to oral anticoagulants. (38, 65, 66) 
Chloral hydrate variably effects the anticoagulant response 
to oral anticoagulants. (38, 65, 66) 
01368 Chloramphenicol 
Chloramphenicol may potentiate oral anticoagulants (64), 
( diphe nylhydantoin (67) and sulfonylureas (67). 
01406 Diuretics 
Diuretics producing potassium and magnesium deficiencies 
may precipitate digitalis toxicity (94, 95). Concomitant use 
with corticosteroids may result in excessive potass ium loss 
(102) . Diuretics may antagonize the activity of oral hypo-
glycemics. (115, 163, 164) 
01449 Cholestyramine 
Cholestyrarnine (Cuemid) may elevate the anticoagulant 
response to oral anticoagulants. (68) It decreases absorp-
tion of thyroid preparations by binding thyroxine and tri iodo-
-47-
thyronnine. (177) 
( 01 481 Clofibrate 
Clofibrate (Atromid S) pharmacologically elevates the 
anticoagulant response to oral anticoagulants (63) . It may 
inhibit platelet adhesiveness. (1 79) 
01546 Colistin 
Coli s tin (Coly-Mycin) enhances neuromuscular blockade 
of skeletal muscle relax ants. (97) Concomitant administra-
tion of parente ra l cephalosporins increases incidence of 
nephrotoxicity. (9 6 ) 
01589 Corticosteroids 
Corticosteroids may be potentiated by estrogens. (99) 
( They m.ay pharma c ologically antagonize hypoglycemics 
(77, 115) and decrease salicylate plasma levels (1 5). Diphenyl-
hydantoin may d e crease therapeutic response to corticosteroids. 
(100, 101) Concomitant use with diuretics may result in ex-
cessive potassium loss. (102) 
0162 7 Corticotropin 
Corticotropin (ACTH) may be potentiated by estrogens (99). 
It may pharmacologically antagonize hypoglycemics (77, 115) 
and de crease salicy l ate plasma levels (15). Diphenylhydantoin 
may decrease re s ponse to corticosteroids. (100, 101} Concomi-
tant use with diuretics may result in excess i ve potassium loss. 
( (102) 
f 
( 
( 
01678 Dapsone 
Dapsone (A vlosulfon) plasma l evels are increased by 
probeneci.d (Benemid). (103) 
01759 Digita~s Glycosides 
Digitalis glycosides are pharmacologically potentiat-
ed by parenteral calcium preparations (7 4, 75) and diuretics 
producing potassium and magnesium deficiencies (94, 95). 
Arnphotericin B (Fungizone) may produce hypokalemia pre-
cipitating digitalis toxicity. (82) Sympathomimetics may 
increase i ncidence of cardiac arrhythmias . (94 ) 
01 791 Diphenylhydantoin 
Diphenylhydantoin is potentiated by chloramphenicol 
(67), disulfir arn (Antabus e ) (10 5) and isoniazid (106, 107). It 
may be antagonized by ethyl alcohol (104) and phenyramidol 
(Analexin ) (10 9). It _may potentiate oral anticoagulants {69) 
and methotrexate (108). It may decrease the therapeutic 
response to corticosteroids. (100, 101) 
0184~ Dipyridamo~ 
Dipyridamole (Persantine) may potentiate the anticoagu-
lant activity of heparin. (110~ 178} 
01880 Disulfiram 
Disulfira m (Antabuse ) potentiates diphenylhydantoin. (105) 
Concomitant use with isoniazid (111), ethyl alcohol (30) and 
-48-
( 
metronidazole (Flagyl) (112, 113) enhances the incidence of 
adverse effects. 
0192 9 Echothiophate Iodide 
Echothiophate iodide (Phospholine iodide) potentiates the 
pharmacological effects of succinylcholine. (114) 
01961 Ephedrine 
Ephedrine potentiates hypertensive reactions with MAOI. 
(23) It antagonizes the adrenergic neuron blockade produced 
by guanethidine (Ismelin). (40 ) 
02011 Epirnpl~Jn~ 
Epinephrine , and to a les ser extent, other adrenergic 
a gents may decrease activity of hypoglycemic agents. (11 5) 
02062 Estrogens 
Estrogens pharmacologically elevate the anticoagulant 
activity of o r al anticoagulants. (98) They may potentiate 
corticosteroid activity. (99) 
02100 ~thacrynic Acid 
Ethacrynic acid potentiates ototoxicity of aminoglycos i de 
antibiotics. (11 6) It may produce potassium and magnesium 
deficiencies precipitating digitalis toxicity. (94, 95) Con-
comitant use with corticosteroids may enhance potassium l oss . 
(102) It may antagonize the activity of oral hypoglycemics. 
(163, 164) 
-49-
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02143 Ethchlorvynol 
( Ethchlorvynol (Placidyl) antagonizes the anticoagulant 
·activity of oral anticoagulants. (11 7) 
0219 4 Folic Acid 
Folic acid antagonizes the antineoplastic activity of 
methotrexate . (11 8) 
02 2 32 Fu r osemide 
Furosemide may produce potassium a nd magnesium de-
fici encies precipitating digitalis toxicity. (94, 95) Concomit ·-
ant use with corti costeroids may enhance potass ium loss. 
(10 2 ) It enhances the effects of iubocurarine. (119) It may 
antagonize the activity of oral hypoglycemics. (163, 164) 
( 02 275 Gentamicin 
Gentamicin in combination with other aminogl ycoside anti-
biotics increases incidence of ototoxicity and nephrotoxicity. 
(120) Ethacrynic acid potentiaies the ototoxicity. (11 6) It 
enhances the blockade of skeletal muscle relaxants. (97) 
0 2 313 Gl utethimide 
Glutethimide (Doriden) decreases anticoagulant response 
to oral anticoagulants. (49, 70) 
02364 Glyc~_ry~ Guaiacolate 
Glyceryl guaiacolate may potentiate the anticoagulant 
( 
( 
( 
( 
activity of heparin. (110, 118} 
02 402 Griseofulvin 
Griseofulvin may decrease the anticoagulant activity 
of oral anticoagulants . (28, 73) It is antagonized by bar-
biturates which may impair absorption. (37) 
02 445 Guanethidine 
Guanethidine may b e potentiated by procainamide (125), 
propranolol (1 26 ) and quinidine (127). It is antagonized by 
amphetamines (40), tricyclic antidepressants (60, 61, 62), 
ephedrine (40) and methylphenidate (40, 122,123). It may 
potentiate phenylephrine (124) and decrease activity of hy-
p oglycemics (88, 89). Ethyl alcohol (2 9), methotrimepra·-
zine (Levoprome) (121), procarbazine (l\!Iatulane ) (48) and 
thiazide diuretics (32) may potentiate orthostatic hypotension. 
02496 Heparin 
Heparin induced anticoagulant activity may be enhanced 
by dipyridamole (Persantine) (11 O) and glyceryl guaiacolate 
(110, 118). 
02542 Hypoglycemic Agents, Oral 
Oral hypoglycemic agents may be potentiated by chloram-
phenicol (67). l\IIAOI (22), phenylbutazone (Butazolidin) (2, 165), 
propranolol (Inderal) (166, 16 9 ), bishydroxycoumarin (162), 
- 51-
-52-
phenyramidol (Analexin) (162) and salicylates (17). The hypo-
( glycemic effects are antagonized by corticosteroids (77 ), 
diuretics (115, 163, 164) and guanethidine (lsmelin) (88, 89). 
02585 Indomethacin 
Indomethacin may pharmacologically e l evate the activity 
of oral anticoagulants. (71) Indomethacin plasma levels may 
b e increased by probenecid (Benemid ) (1 28) and decreased by 
salicylates (53 }. 
02623 Insuhn 
------~---·~..;... 
Insulin may be pha rmacologically antagonized by guanethi-
dine. (88, 89 ) Ethyl alcohol may prolong the action of insulin. 
(129) Glucocorticoids, thyroid, epinephrine and thiazide 
diuretics may increase insulin requirements. (115) 
02674 Iron Salts 
Iron salts should not be used simultaneously with allopur-
inol (Zyloprim). (1 40) Antacids may dec rease iron absorption. 
(141) I ron salts may impair the absorption of oral tetracy-
clines. (183) 
02 712 Isoniazid 
I soniazid increases plasma levels of diphenylhydantoin . 
(106, 107} It may be antagonized by ethyl alcohol. (1 30 ) 
Concomitant use with disulfirarn (Antabuse ) (111) and meper-
idine (131) enhances incidence of adverse effects. 
-53-
01 716 D-Thyroxine 
( D-Thyroxine elevates the anticoagulant re s ponse to 
' 
ora l anticoagulants. (63) 
02755 Isoproterenol 
Isoproterenol is pharmacologica lly antagonized by pro-
pra nolol (Inderal). (132) 
02 801 Kanamycin 
Kanamycin in combination with other aminoglycoside 
antibiotics increases incide nce of ototoxicity and nephrotox_-
icity . (120) Concomitant use with ethacrynic acid potentiates 
the ototoxicity. (116) It potentiates neuromuscular blockade 
of skeletal muscle relaxants. (97) When administered by the 
( oral route it may increase the activity of oral anticoagulants. 
(64) 
02 852 Kaolin-Pectin 
Kaolin-pectin mixtures inhibit the absorption of o rally 
administered lincomycin (Lincocin), (133) 
028 95 Levodopa 
Levodopa may be antagonized by methyldopa (137), pyri -
doxine (138 , 139), res erpine (137) and phenothiazines (85) . 
Concomitant use with MAOI may produce hypertens ion (136). 
Additive therapeutic effects may occur with amantadine 
(Symmetrel ). (9) 
( 
( 
02933 Lithium Carbonate 
Lithium excretion is increased by amjnophylline (134), 
sodium bicarbona te (134) and large doses of sodium chloride 
(1 35). Low sodium intake may precipitate lithium. toxicity. 
(135) 
_02 98~}Aagnesii:m Salts 
Magnesium ions administered parenterally potentiate the 
neuromuscular blockade of skeletal muscle relaxants. (142) 
0303.4 Meperid~~ 
Meperidine should not be used simultaneously with i sonia-
zid (131) and MAOI (25) - it enhances incidence of adverse 
effects. It is potentiated by other CNS depressants. 
03_0 77 Meprobamate 
Meprobamate (Equanil, Miltown) is potentiated by ethyl 
alcohol. (180, 1 81) 
03115 Mercaptopurine 
Mercaptopurine (Purinethol) is potentiated by allopurinol 
(Zyloprim). (11 , 58) 
03166 Metaraminol 
Metaraminol (Aramine) is pharmacologically potentiated 
by MAOI. (23) 
03 204 Methenamine Compounds 
Methenamine compounds exhibit optimum activity in a 
-54-
( 
( 
urine ph of 5. 5 or lower . Urine ac idifying agent s a re use -
ful adjuncts while urine a lkalinize rs decrease activity . 
(14 3) Conco mitant use with sulfonamides frequently r es ults 
in crystalluria and the formation of a precipitate. (143, 144 
145) 
~~47 M_ethoxyflurane 
Mcthotrcxate se rum levels are e l evated by diphenylhy-
dantoin (10 8), salicylates (16, 146, 147 ) and sulfonamides (16, 
146, 147) . It may impa ir the immunological response to 
smallpox vacc ine, resulting in vaccina . (148) 
032 98 Methotrimeprazine 
Methotri mepraz ine (Levoprome) potenti ate s the effects 
of antihypertens ive agents (1 49 ), other CNS depres sants (149 ) 
and skeletal muscle r elaxants (149). It will produce extrapy-
ramidal symptoms when us ed simultaneously with anticholine r-
gi cs. (1 49) 
03361 Methoxyflu r ane 
l\/[ethoxyflurane anesthesia in conjunction with t etracycline 
therapy increases incidence of nephrotoxi c effects. (93) 
03344 Methyldopa 
Methyldopa n1ay antagoni ze the the rapeutic effects of 
l evodopa (1 37). Additive hypotensi ve effects may occur with 
propranolol (Inde ral) (84, 150), procainamide (Pronestyl) 
-55-
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(125, 168), methotrimeprazine (Levoprome) (149) and thiazide 
( 
diuretic s (184). 
-03387 Methlyphenjdate 
Methylphenidate (Ritalin) potentiates tricyclic antidepressants. 
(34) It may be potentiated by MAOI. (20, 151) It antagonizes the 
pharmacological effects of guanethidine (Ismelin ). (40, 122, 123) 
03 425 Metroni dazole 
Metronidazole (Flagyl) should not be used simultaneously with 
disulfi ram (Antabuse ) (112, 113) or ethyl alcohol (31) due to the in-
creased incidence of adverse effects . 
03476 Monoamine Oxidase Inhibitors 
Monoamine oxidase inhibitors potentiate the pharmacological 
( 
effects of amphetamines (20), methylphenidate (Ritalin) (20, 151). 
tricyclic antidepressants (21), hypoglycemics (22) and sympatho-
mimetics such as ephedrine (23), metaraminol (Aramine ) (24), 
pheny l ephri.ne and phenylpropanolamine. Concomitant use with 
meperidine (25) or levodopa (13 6 ) increases incidence of adverse 
effects. 
03514 Nafcillin 
Nafcillin (Unipe n) plasma levels are increased by concomitant 
use of probenecid (Benemid). (154) 
03557 Neomycin 
"' 
Neomycin in combination with other aminoglycoside antibiotics 
( 
( 
-57-
increases incidence of ototoxicity and nephrotoxicity. (120) 
Concomitant use with ethacrynic acid pote ntiates the ototoxicity. 
"(11 6) It potentiates neuromuscular blockade of skeletal muscle 
relaxants. (97) When adrn.inistered by the oral route it may in-
crease the acti vity of oral anticoagulants. (64) 
Q.~603 Nitroglyceri n 
Nitroglycerin may produce hypotension following combined use 
with ethyl alcohol. (2 7) Chronic administration of pentaerythritol 
tetranitrate (Peritrate ) may produce a tolera nce to nitroglycerin. 
(152, 153) 
036 97 Orphenadrine 
Orphenadrine (No rflex) in combination with propoxyphene 
(Darvon) may produce mental confusion and anxiety. (16 9, 1 70) 
037 35 Oxyphenbutazone 
Oxyphenbutazone (Ta ndearil) elevates the anticoagulant res-
ponse to oral a nti coagulant s. (28, 3 9) Oxyphenb utazone plasma 
levels may b e elevated by anabolic ste roids. (15 5, 156 ) 
037 43 Penicillin G and Derivatives 
P enicillin G and derivati ves-plasma l evels are e l e vated by 
probenecid (Be nemid ) (8, 43 ) and salicylates (14) . 
0 3751 Pentaerythritol Tetranitratc 
Pentaerythritol tetranitrate (Peritrate) therapy may produce 
a tolerance to nitroglycerin . (152, 15 3) 
-58-
037 86 Phenothiazines 
Ph enothiazines may antagonize levodopa (85) and the central 
·effects of amphetamines (41). Additive effects occur with con-
comitant use of other C NS depressants (161) and antihista mines 
(157) . A dditive cardiac de pres sant effects are possible with quini-
dine. (1 58, 159 , 160) Procarbazine (Matulane ) may potentiate the 
CNS depressant effects of phenothiaz ines. (48) 
03824 Phe11ylbutazone 
PbenyJ.butaz one (Butazolidin) elevates the anticoagulant response 
to oral anticoagulants (2 8, 39) and pote ntiates the hypoglycemi c re-
sponse to sulfonylureas (2 , 165) . Phenylbutazone plasma l evel s 
may b e e levated by anabolic steroids. (15 5, 15 6) 
( 0 386 7 Pheny lephrine 
Pheny l ephrine administered nasally or systemically may be 
potentiated by guanethidine (Isme lin) (124) and MAOI (23). 
03905 Phenylpropanolamine 
Phenylpropanolamine may b e pote ntiat ed by MAOI. (23) 
03 956 P henyramidol 
Phe nyramidol (Ana lexin) elevates t he a nticoagulant r esponse 
to oral anticoagulants (72) and potentiates the a ctivity of diphe nyl-
hydantoin (109) and sulfonylureas ) (1 62). 
03 999 Polymyxin B 
Polymyxin B (Aerosporin) enhances ne uromuscular blockade 
of skel etal muscl e relaxants. (97 ) In cornbination with other 
-59-
( a minoglycoside antibiotics it inc reases incidence of ototoxicity 
and nephrotoxicity. (120) 
·04230 Probenecid 
Probenecid (Benemid) elevates plasma levels of aminosalicylic 
acid (81), dapsone (Avlosulfon) (103), cephalosporins (43, 77), peni-
cillin G and derivatives (8, 43) and indomethacin (128). Salicylates 
inhibit uricosuric activity of probenecid. (19) 
040 73 Procainamide 
Procainamide (Pronestyl) - additive hypotens i ve effects may 
occur with concomitant use of antihypertensi ve agents. (12 5, 16 8 ) 
04138 Procarbaz ine 
Procarbazine (Matulane) may potentiate the effects of phen-
( 
othiazines and CNS depressants. (48) It may produce additive 
hypotensive effects with guanethidine (Ismelin) . (48) 
041 70 Propoxyphene 
Propoxyphene (Darvon) in combina tion with orphenadrine 
(Norflex ) may produce mental confusion and anxiety. (169, 170) 
04219 Propranolol 
Propranolol (Inderal) may potentiate oral hypoglyc emics (166, 
167) and antihypertensives {84, 126). It antagonizes pharmacolo-
gical actions of sympathomimetics. (132) Propranolol-induced 
adverse effects are antagonized by anticholinergics. {84) Addi-
tive cardiac depre ssant effects are possible with quinidine (171, 
( 
( 
172) and phenothiazines (158, 159, 160) 
042 51 Pyridoxine 
-60-
Pyridoxine (Vitamin B6) antagonizes the pharmacological ef-
fects of levodopa. (138, 139) 
0430 8 Quinidine 
Quinidine may potentiate guanethidine (127), o ra l anticoagulants 
(28 , 185) and the neuromuscular blockade of mu s cle relaxants (173). 
It may b e poi.enti8.ted by anticholinergics (83). Ac etazolarnide 
(Diamox ), sodium bicarbonate and thiazid e diuretics increase renal 
reabs orption (5, 78, 175). Additive cardiac depre s sant effects are 
pos s ible with propranolol (171 , 172) and phenothiazines (15 8, 159, 
160). 
04 34 0 Reserpine 
Res e rpine is p otentiated by methotrimeprazine (Levoprome ). 
(14 9) It may antagonize the e ffects of l evodopa. (137) 
043 83 Salicyl ates 
Salicylate s elevate the anticoagulant response to oral anticoag-
ulants (13), inc rease plasma l evels of unbound penicillin G and 
de ri vatives (14) and potentiate methotrexate (16) and sulfonylureas 
(17). Salicyla te plasma levels may be decreased by corticosteroids. 
(15 ) They may decrease se r um levels of indomethacin (Indoc in) 
(53) and i nhibit uricosuric activity of sulfinpyrazone (Anturane ) 
(18) and probene cid (Benemid) (19). 
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04421 Skeletal Muscle Relaxants ( 
Surgical skeletal muscle relaxants are potentiated by ami no-
glycoside antibiotics (97), amphotericin B (82 ), furosemide (11 9), 
magnesium ions (142 ), rnethotrimeprazine (Levoprome} (1 49 ), quini-
dine (173} and thiazide diuretics (174). Echothiophate iodide poten-
tiates the effects of succinykholine. (114) 
0<1472 Small Pox Vaccine 
·---·------
Small pox vaccination may result in generalized vacci na with 
concomita ~1t use of methotrexate. (148) 
04510 Sodium Bicarbona te 
Sodium bicarbonate elevates serum levels of amphetamines 
(42), tricyclic antidepressants (33, 37) and quinidine (5, 78, 175) 
( 
by enhancing renal reabsorption. It may antagonize methenamine 
compounds (143) and lithium carbonate (1 34) and decrease oral 
absorption of tetracyclines (91). 
04553 Sodium Chloride 
Sodium chloride in large doses may antagonize pharmacologi-
cal effects of lithium carbonate. (135) Low sodium intake may 
precipiiate lithium toxicity. (135) 
04618 Sodium Polystyrene Sulfonate 
Sodium polystyrene sulfonate resin (Kayexa late) binds mag-
nesium and calcium ions found in antacids resulting in systemic 
alkalosis. (176) 
( 
( 
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04650 Strept~~ycin 
Streptomycin in combination with aminoglycoside antibiotics 
increases incidence of ototoxicity and nephrotoxicity. (120) 
Ethacrynic acid potentiates the ototoxicity. {116) It potentiates 
neuromuscular blockade of skeletal muscle relaxants. (9 7) 
04693 Sulfi~pyrazone 
Sulfinpyrazone (Anturane) induced uricos uria i.s inhibited by 
salicylates. (18) 
04731 Sulfonamides 
Sulfonamides may potentiate the hypoglycemic response to 
oral hypoglycemics (1) and elevate serum levels of methotrexate 
{16, 146, 147). Concomitant use with methenamine compounds 
frequently results in crystalluria and the formation of a precipitate. 
(143, 144, 145) 
04782 Tetracyclines 
Tetracycline absorption is decreased by antacids (90) contain-
ing divalent or trivalent cations, sodium bicarbonate (91) and iron 
salts (183 ). It may elevate anticoagulant response to oral anti-
coagulants (92) and potentiate nephrotoxic effects of methoxyflurane 
(Penthrane) (93 ). 
04820 Thiazide Diuretics 
Thiazide diuretics may precipitate digitalis toxicity (94, 95 ) 
and antagonize the effects of hypoglycemics (115, 163, 16 4 ). Neuro-
( 
( 
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muscular blockade produced by surgical muscle relaxants may be 
enhanced. (174) Concomitant use with corticosteroids may result 
in excessive potassium loss. (162) They may produce ad ditive 
hypotensi ve effects ·with guanethidine (Ismelin) (32) and methyldopa 
{Aldomet ) (184). 
04863 Thyroid Prepa rations 
Thyroid preparations may potentiate the anticoagulant response 
to oral anticoagulants. (63) Cholestyramine decreases absorption 
by binding thyroxine and triiodothyronnine. (177) They may de-
crease activity of hypoglycemic agents. (115) 
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Alpha betical Cros s-Index 
A 
Ac e nocoumarol 008 25 Benzestrol 02062 
Acetaminophe n 00086 Benzthiazide 04820 
Acetazolamide 00124 Bethamethasone 01589 
Acetohexamide 02 542 Bipe riden 00787 
Acetophenazine Biphetamine-T 00698 
Male ate 03786 Bisacodyl 010 90 
A cetyldigitoxin 017 59 Bishydroxycoumarin 01058 
Aldactazide 04820 Butabarbital Sodium 00 95 7 
Adiphenine HC1 007 87 Butalbital 00957 
Allopurinol 00205 Butaperazine 
Alphap rodine 002 56 Maleate 03786 
Alve rine Citrate 00787 Butazolidin Alka 03824 
Amantadine 00337 
Aminophyllin 00434 c 
Aminosalicylic Acid 00515 
Amitriptyline HCl 00876 Calcium Chloride , 
Amm onium Chloride 00566 Injection 01139 
Amo barbital 00957 Calcium Gluconate, 
Amphetamine Injection 01139 
Sulfate 00698 Car be nicillin 01147 
Amphotericin B 00604 Carbr ital 00957 
A mpicillin 00647 Carphenazine 
Agiotensin Amide 00744 Male ate 03786 
Antacids 00299 Cholestyramine 01449 
APC 04383 Chlora l Betaine 01236 
Aprobarbital 00957 Chloral Hydrate 01317 
Ascorbic Acid 00914 Chloramphenicol 01368 
Aspirin 043 83 Chlormerodrin 01406 
Atropine Sulfate 00787 Chlorothiazide 04820 
A zapetine HCl 00892 Chlorotrianisene 02062 
Azo - Gantanol 04731 Chlorpromazine 
Azo-Gantrisin 04731 HCl 03786 
Chlorpropamide 02542 
B Chlortetracycline 04782 
Chlorthalidone 01406 
Barbital 00957 Clofibrate 01 48 1 
Barbital Sodium 00957 Coli s tin 01546 
Bendroflumethiazide 04820 Corn bid 03786 
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Corticotropin 01627 Doxycycline 04782 
~r Cortisone 01589 D-Thyroxine 01716 
C-Quc ns 02062 Dyazide 04820 
Cyclothiazide 04820 
Cycrimine HCl 00787 E 
Cyproheptadine HC 1 00884 
Echothiophate Iodide 01 929 
D Empirin 04383 
Ephedrine 01961 
Dapsone 01678 Epinephrine 02011 
Darvon Compound 04170 Eskatrol 00167 
04383 03786 
Darvon Compound-65 04170 Estradiol 02062 
04383 Estradiol Benzoate 020 62 
Decamethoniurn E stradiol Dipropio-
Bromide 0442 1 nate 02062 
Demethylchlor- Estrone 02062 
tetracycline 04782 Equagesic 03077 
Desbutal 006 98 04383 
00 957 Ethacrynic Acid 02100 
Desipra mine HCl 00 876 Ethchlorvynol 02143 
Deslanoside 01759 Ethinyl Estradiol 02062 
Dexamethasone 01589 Ethyl Alcohol 00167 ., 
.. 
( Dexamyl 00698 Ethyl Biscoumacctate 00825 
00957 Ethylestrenol 00752 
Dextroamphetarnine 
Sulfate 00698 F 
Dibutoline Sulfate 00787 
Diene strol 02062 Ferrous Fumarate 02674 
Diethy lstilbestrol 02062 Ferrous Gluconate 02674 
Diethylstilbestrol Ferrous Sulfate 02674 
Di phosphate 02062 Fludrocortisone 01589 
Digita lis 01'759 Fluphenazine Enan-
Digitalis Glycosides 01759 thate 03786 
Digitoxin 01759 Fluphenazine HCL 03786 
Digoxin 01759 Fluprednisolone 01589 
Dimethyl Tubocura- Folic Acid 02194 
rine Iodide 04421 Furosemide 02232 
Diphenhydramine 
Hydrochloride 00884 G 
Diphenylhydantoin 01791 
Dipyridamole 01848 Gentamicin 02275 
Disulfiram 01880 Glutethimide 02313 . 
Diupres 04340 Glyceryl Guaicolate 02364 
04820 Gris eofulvin 024 02 
( Doxepin HCL 00876 Guanethidine 02445 
( H 
Heparin 
Hetacillin 
i-Iexafluorenium 
Bromide 
Hexobarbital 
Hydrochlorothiazide 
Hydroc ortiso ne 
Hydroflumethiazide 
Hydropres 
I 
Irnipran1ine 
Indomethacin 
Insulin 
Isocarboxazid 
Isoniazid 
Is op roterenol 
K 
Kanamycin Sulfate 
Kaolin-Pectin 
L 
Lanatoside C 
Levodopa 
Levothyroxine 
L-Hyoscyamine Sulfate 
Liothyronine 
Liotrix 
Lithium Carbonate 
M 
Magnesium Sulfate, 
Injection 
Meperidine HCL 
Mephobarbital 
Meprobamate 
Meralluride 
Mercaptomerin Sodium 
Mercaptopurine 
02496 
00647 
0442 1 
00957 
04820 
01589 
04820 
04340 
00876 
02585 
02633 
03476 
02712 
02801 
02852 
01757 
02895 
0486;3 
00787 
04863 
0486 3 
02933 
02984 
03034 
00957 
03077 
01406 
01406 
03115 
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Mercurophylline 01406 
Merethoxylline 01406 
Metaraminol 03166 
Methacycline 04782 
l\/Iethallenestril 02062 
Methamphetamine HCL 00698 
lVIethandriol 00752 
l\/Iethandrostenolone 00752 
Methdilazine I-lCL 00884 
Methenamine Hippur-
ate 03204 
Methe namine Man -
delate 
Methenamine Sul-
fosalicylate 
Methotrexate 
Methotrimeprazine 
Methoxyflurane 
Methyclorthiazide 
11ethylatropine Nitrate 
Methyldopa 
l\![ethylphenidate 
Metby lprednisolone 
Metronidazole 
N 
Nafcillin 
Naldecon 
Nandrolone Decanoate 
Nandrolone Phen-
propionate 
Neomycin 
Nialamide 
Nitroglycerin 
Norethandrolone 
Norge sic 
Nortriptyline HCL 
0 
Orphenadrine 
Ortho-Novum 
03204 
03204 
03247 
03298 
03361 
04820 
00787 
03344 
03387 
01589 
03425 
03514 
03905 
00752 
00752 
03557 
03476 
03603 
00752 
03697 
04383 
00876 
03697 
02062 
-67-
Ovral 02062 Propranolol 04219 
( Ovulen 02062 Protriptyline HCL 00876 
Oxymetholone 00752 Pyridoxine 04251 
Oxyphenbutazone 03735 
bxytetracycline 04782 Q 
p Quabain 01759 
Quinetha zone 01 4 06 
Paramethasone 01589 Quinidine 04308 
Penicillin G 03743 
Pentacrythritol R. 
Tetranitrate 03751 
Pentob2rbital Sodium 00957 R.eserpine 04340 
Perphenazine 03786 
Phenelzine 03476 s 
Pheniorrnin 02542 
Phenindione 00825 Salicylamide 04383 
Phenobarbital 00957 Scopolamine HBr 00787 
Phenoxybenzamine Secobarbital 00957 
Hydrochloride 00892 Ser -Ap-Es 04340 
Phenoxymethyl 04820 
P enicillin 03743 Small Pox Vaccine 04472 
Phenylbutazone 03824 Sodium Bicarbonate 0451 0 
( Phenprocoumon 00825 So di um Chloride 04553 
Phenylephrine 03867 Sodium Polystyrene 
Phenylpropanolamine 03905 Sulfonate R.esin 04618 
Phenyramidol 03956 Sodium Salicylate 043 83 
Piperactazine 03786 Stanozolol 00752 
Piperidolate 00787 Streptomycin 04660 
Polyestradiol Phosphate 02062 Succinylcholine 
Polymyxin B 03 999 Chloride 04421 
Polythiazide 04820 Sulfachlo rpyridazine 047 3 1 
Prednisone 01589 Sulf adiazine 04731 
Prednisolone 01589 Sulfadimethoxine 04731 
Probenecid 04030 Sulfaethidole 04731 
Procainamide 04073 Sulfarn.erazine 04731 
Procaine Penicillin 03743 Sulfameter 04731 
Procarbazine 04138 Sulfamethizole 04731 
Prochlorperazine 03786 Sulfamethoxazole 04731 
Procyclidine HCL 00787 Sulfamethoxypyri ... 
Promazine 03786 dazi.ne 04731 
Promethazine HCL 03786 Sulfa pyridine 04731 
Promethestrol Sulhnpyrazone 04693 
Di propionate 02062 S ulf is oxaz ole 04731 
Propoxyphene HCL 04170 
Propoxyphene Napsylate 04170 
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T ( 
Tetracycline 04782 
';L'hiopropa za te 
Dihydrochloride 03786 
Thiori dazj_ne HCL 03786 
Thyroglobulin 04863 
Thyroid 04863 
Tolaz oline HCL 00892 
Tolbutamide 02524 
Tolinase 02542 
Tranylcypromine 03476 
TriamcinoJone 01589 
Triamterene 01406 
Trichlorrnethiazide 04820 
Trifluoperazine HCL 03786 
Triflupromazine 03786 
Trihexyphenidyl 00787 
Trimeprazine 00884 
Trimethaphen Cam-
sylate 00892 
Tripelennamine 00884 
Tubocurarine Chloride 0442 1 
( 
w 
Warfarin Sodium 00825 
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Message Code Index 
Message Message 
Code Drug Code Dru IL 
----
0008 6 Acetaminophen 00744 Angiotensin 
00124 Acetazolamide 007 52 Ethy le st re nol 
Methandriol 
00167 Ethyl Alcohol Methandrosteno-
lone 
00205 Allopurinol Nandrolone 
Decanoa te 
002 56 Alphaprodine Nandrolone Phen-
propionate 
00299 Antacids Norethandrolone 
Oxymetholone 
00337 Amantadine Stanozolol 
00434 Aminophyllin 00787 Adiphenine HCL 
( Alverine Citrate 
00515 Aminosalicylic Atropine Sulfate 
Acid Biperiden 
Cycrimine HCL 
00566 Ammonium Chloride Dibutoline Sulfate 
1-Hyoscyamine 
00604 Amphotericin B Sulfate 
Methylatropine 
00647 Ampicillin Nitrate 
Hetacillin Piperidolate 
Scopolarnine HBr 
00698 Amphetamine Trihexyph enidyl 
Sulfate Procyclidine HCL 
Biphetamine-T 
Desbutal 00825 Acenocoumarol 
Dexamyl Ethyl Biscournace-
Dextroampheta- tate 
mine Sulfate Phenindione 
Eskatrol Phenprocoumon 
Methamphetarn.ine Warfarin Sodium 
HCL 
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Message Message 
( Code Drug Code Dr~ 
----
00876 Amitriptyline HCL 01090 Bisacodyl 
Desipramine HCL 
Doxepin HCL 01139 Calcium Chloride, 
Imipramine Injection 
Nortriptyline HCL Calcium Gluconate, 
Protriptyline HCL Injection 
00884 Cyproheptadine Hydro-01147 Carbenicillin 
chloride 
Diphenhydramine 01236 Chloral Betaine 
Hydrochloride 
Methdilazine Hydro- 01317 Chloral Hydrate 
chloride 
Trimeprazine 01368 Chloramphenicol 
Tripelennamine 
01406 Chlormerodrin 
00892 Azapetine Chlorthalidone 
Hydrochloride Meralluride 
Phenoxybenzamine Merethoxylline 
Hydrochloride Mercaptomerin .... 
( Tolazoline Sodium 
Hydrochloride Mercurophylline 
Trimethaphen Quinethazone 
Camsylate Triamterene 
00914 Ascorbic Acid 01449 Cholestyramine 
00957 Amobarbital 01481 Clofibrate 
Aprobarbital d ~ 
Barbital 01546 Colistin 
Barbital Sodium 
Butabarbital Sodium 01589 Betamethasone 
Butalbital Cortisone 
Carbital Dexamethasone 
Desbutal Fludrocortisone 
Dexamyl Fluprednisolone 
Hexobarbital Hydrocortisone 
Mephobarbital Methylprednisolone .li ""1 
Pentobarbital Sodium Paramethasone ; 
Phenoba rbital Prednisolone '" 
Secoba rbi tal Prednisone 
Triam.cinolone 
01058 Bishydroxycoumarin 
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Message Message 
( Code Drug 
---
Code D~~~L 
01627 Corticotropin Ovral 
Ovulen 
01678 Dapsone Polyestradiol 
Phosphate 
01716 D-Thyroxine Promethe strol 
Dipropionate 
01759 Acetyldigitoxin 
Deslanoside 02100 Ethacrynic Acid 
Digitalis 
Digitalis Glycosides 02143 Ethchlorvynol 
Digitoxin 
Digoxin 02194 Folic Acid 
Lanatoside c 
Quabain 02232 Furosemide 
017 91 Dipheny lhydantoin 02275 Gentamicin 
01848 Dipyridamole 02313 Glutethimide 
01880 Disulfiram 02364 Glyceryl Guaiaco-
late 
0192 9 Echothiophate 
Iodide 02402 Griseofulvin 
01961 Ephedrine 02445 Guanethidine 
02011 Epinephrine 02496 Heparin 
02062 Benzestrol 02542 Acetohexamide 
C-Quens Cblorpropamide 
Chlorotrianisene Tolbutamide 
Dienestrol Tolinase 
Diethylstilbestrol Phenformin 
Diethylstilbestrol 
Diphosphate 02585 Indomethacin 
Estradiol 
Estradiol Benzoate 02633 Insulin 
Estradiol 
Dipropionate 0267 4 Ferrous Fumarate 
Estrone Ferrous Gluconate 
Ethinyl Estradiol Ferrous Sulfate 
Methallenestril 
( Ortho-Novum 02712 Isoniazid 
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Message Message 
( Code Drug Code Dr ug 
02755 Isoproterenol Phe nelzine 
Sulfate 
02801 Kanamycin Tranylcyprom ine 
02852 Kaolin-Pectin 03514 Nafcillin Sodium 
028 95 Levodopa 03557 Neomycin Sulfate 
02933 Lithium Carbonate 03603 Nitroglycerin 
02 984 Magnesium Sulfate, 03697 Norges ic 
Injection Orphe nadrine 
03034 Meperidine 03735 Oxyphe nbutazone 
03077 Equagesic 03743 Penicillin G 
Meprobamate Phenoxymethyl 
P e nicillin 
03115 Mercaptopurine Procaine 
Penicillin 
03166 M etaraminol 
03751 P e ntaerythritol 
03204 Methenamine Tetranitrate 
Hippurate 
Methenamine 03786 Ac etophenazine 
Mandelate Male ate 
Methe namine Butaperazine 
Sulfosalicylate Male ate 
Carphenazine 
03247 Methotrexate Male ate 
Chlorpromazine 
03298 Methotrimeprazine HCL 
Comb id 
03344 Methyldopa Eskatrol 
Fluphenaz ine 
03361 Methoxyflurane Enant hate 
Fluphe nazine 
03387 Methylphenidate HCL 
Perphenazi ne 
03425 Metronidazole Pipe ractazine 
Prochlorperazine 
03476 Isocarboxazid HCL 
Nialamide Promazine HCL 
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Message Message 
( Code Drug Code Drug 
Promethazine HCL 04383 APC 
Thiopropazate Aspirin 
Dihydrochloride Empirin 
Thioridazine HCL Equages ic 
Trifluoperazine Norge sic 
HCL Salicylamide 
Triflupromazine Sodium Salicylate 
03824 Butazolidin Alka 04421 Dim ethyl Tubo-
Phenylbutazone curarine Iodide 
Decamethonium 
03867 Phenylephrine Bromide 
Succiny lcholine 
03 905 Naldecon Chloride 
Phenylpropanolamine Tuboc urarine 
Chloride 
03 956 Phenyramidol 
04472 Small Pox 
03 999 Polymyxin B Vaccine 
( 04030 Probenecid 04510 Sodium Bicar-
bona te 
04073 Procainamide 
04553 Sodium Chloride 
04138 Proca rbazine 
04618 Sodium Polysty-
04170 Darvon Compound r ene Sulfonate 
Darvon Compound-65 Res in 
Propoxyphene HCL 
Propoxypbe ne 04660 Streptomycin 
Napsylate 
04693 Sulfinpyrazone 
04219 Propranolol 
04731 Azo -Gantrisin 
04251 Pyridoxine Azo-Gantanol 
Sulfadiazine 
04308 Quinidine Sulfaethidole 
Sulfachlorpyri-
04340 Di up res dazine 
Hydropres Sulfadirnethoxine 
H.es e rpine Sulfam_erazine 
Ser-Ap-Es Sulfameter 
( Sulfamethizole 
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Message 
( Code Drug 
Sulfamethoxazole 
Sulfamethoxypy-
ridaz ine 
Sulfa pyridine 
Sulfisoxazol e 
04782 Chlortet racycline 
Demethylchlort et-
racycline 
Doxycycline 
Methacyc line 
Oxytet ra cycline 
'I'etracycline 
04 820 Alda ctaz ide 
Bendroflumethiaz ide 
Benzt hiaz ide 
Chlorothiazide 
Cyclothia zide 
Di up res 
Dyazide 
Hydrochlorothiazide 
Hydroflumethiazide 
Hydropres 
Meth:yclo rthiazide 
Polythiaz ide 
Ser-Ap-Es 
Trichlormethiazide 
04863 Liothyronine 
Liotrix 
Levothyroxine 
Thy roid 
Thyroglobulin 
( 
( 
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~CETAMINJ PHEN ELEVA TES THE ANTICOAGULANT RESPONSE TO ORA L ANTICOAGU-
LA!HS. 
tCETAZO~ A~lDE tOIA MOX), URINARY ALKALINIZING AGENT, ELEVATES SERU~ 
LEVE LS OF AMFHETAMINES, TRlCYSLIC ANTIDEPRE SSA NTS ~NO QUINIDINE BY 
ENHA NC ING RE~AL REABSUR~ TI ON. IT MAY ANTAGONIZE THE ACTIVITY CF 
METhENA~INE COMPCUNCS. 
ET~YL ALCC HOL-AODITIVE EFFEC TS MAY BE SEEN WITH CNS DEP RE SSANTS ANO 
MH l HIS TAl-1£ 1iES. 1 I MAY ANT.\GONlZE H: E PHARKACOLCGICAL EFFECTS OF THE ORAL 
ANIICOAfULA ~ 1S AND ClPHENYLHYOA~TCIN. IT MAY E~HANCE THE ADVERSE fFFECTS 
OF GLANEIHICINE 0 NITRGG LYCERI~, DISU LF IRAM IANTABUS El, HETRUNIDAZOLE 
{FLAGYL) ANO TKICYCLIC ANTIDEP RESSANTS. IT PROLONGS TH E ACTION OF INSULIN. 
ALLOP URINCL POTENT IATES THE EFFECTS OF BISHYDRUXYCGUMARIN, AND MEkCA P-
TCPURlNE. IT MA Y INCREASE HEPATI C IRC N CONCENTRATION. 
A~TACIDS CO NTAINING DIVALENT AND TRIV ALENT CATIONS DECREASE ORAL 
ABSCRPTION OF TETRACYCLINE S. Ah TACIDS SHDULU NUT BE ADMINISTERED SIMULTAN-
EO USLY hITH ENTERIC CCATEO PRODUCT S. SODIUM POLYSTY RENE RESIN IKAYE XA LATEl 
BINDS MAGNESIUM AND CALCI UM IONS FOUND IN ANTACICS RE SULTI~G IN SYSTEMIC 
ALK/llOSIS. 
Pi'l.ANTACINE ( SYMMETl{EL I POTENT IA1 ES lHE PHARMAC OLOGICAL EfF ECTS 
PROCUCEC BY LEVOCUPA. 
A~INOPHYLLIN HAY IHPAIR lHE THERAPEUTIC RESPONS E TO LITHIU M CAR BONATE 
BY I NCREASI~G lHE RENAL EXCRETION OF LITHIUM IO NS. 
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A~INCSALICYLIC ACID PLASMA LEV ELS ARE ELEVATED BY PROBENECIO <B ENEMlD l 
AM MONIU M CHL ORID E IUUINA RY AC IDIFIE R) MAY DEC REASE RENAL REABSORPJION 
OF AMPHETA M I~ES AND TRICYCLlC ANTI DE PR ESS AN TS. 
AMPHOTE RICT N B CFU NGIZONE) MAY PR ODUCE HYPCKALE MIA PRECIPITATING 
DIGITALIS TO XI CITY. IT KAY POTENTI AT E NEUROMUSC~LAR BLOCKAUE OF 
SKELETAL MU SCLE RELAXA NTS. 
A MPICJLLI ~ PLASMA L~ VE LS ARE INCREAS ED BY CO NCOMITANT USE OF PROBENECID 
(BE~EM IC). 
AMPHET AM IN ES POl ENTlATE M~OI AND ANTAGONIZE THE EFFECTS OF GUANETH-
IDINE. PHENOTHIAZI~ E S MAY A~TAGONllE THE CENTRAL EFFECTS OF AMPHETAMINES. 
URINE ACIDIFYIN G AGENTS DEC REASE RE NAL RE ABSORPTION AND URINA RY ALKA LI NI-
ZERS SUCH AS ACETAZCLA r ID E (OIA MGXI, SODIUM BICARBONATE AND THIAZIDE 
C!U RETICS INCR EASE kE~BS O~PTlON. 
ANGIOTENSIN AMI DE (H YPEkTENSINJ-lNOUCED ANTICIURESIS AND ANTINATRI-
URESIS IS REVER SED BY ETHAC RYNIC ACID IEDECRIN) ANO FUROSEMIDE (LAS! XI. 
ANABOLIC STEROIDS ~AY POTENTIATE THE ACTIVITY OF ORA L ANTICOAGULANTS, 
PHE~YLHUTAZOhE I BUTAZOLIDINl AN C OXYPH E ~H UTAZCNE (TA NOEARIL). THEY MAY 
CECREASE INS~LIN kE QUlREM ENTS IN DIAB ETICS. 
ANTICHOLI~ERGIC DRUGS MAY POTENTIATE QUINIDI NE ANO THE SECONDARY 
PHARMACOLOGICAL EFFECTS OF ANTIHISTAMl NES AND TRICYCLIC ANTIDEPRESSANTS. 
PROPRA NCLOL (lNOERALl-INOUCED AD~ERSE EFFECTS ARE ANTAGONIZED BY ANT I -
CHOLlNERGICS. THEY MAY PRODUCE EXTRAPYRAMIDAL SYMPTOMS WHEN USED SIMULTAN-
EOUSLY ~ITH ~ETHOTRIMEPRAZINE (LE VOPRO~EJ . 
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ORAL ANl !COAGULANTS ARE POTE~ TIA TEL BY ACETAPINO PHEN , ESTROGENS, 
ANAEOLIC STEROIUS 1 CHLORAMPHENICOL, CHOLESTYRAMINE CCUEP1U l 1 CLOFIBKATE 
<ATRCMIO SJ, 0-T hYROXINE, PHENYLBUTAZO~E (BUTAZCLIDJNI AN O PHENYRAMIOOL 
{A NALEXINl. THEY MA Y BE POTENTIATEO BY AHINOGLY COSIOE ANT I BIOTICS, DI-
PHENYL ~IYO AN TC I~, INOO~ETHACIN, QUINIOJ ~E AND SALI CYLA TES . THEY ARE ANTAG-
ONIZED BY ET~Yl ALCCHOL, BARBI TC RATES, ETHCHLOKVYNOL, G~I S EOFULV I N ANO 
GLUTETHIMIDE. Tl!EY ARE VARIA BLY AFFEC TE D ~y C~LCRAL HYDRATE . 
TRICYCLIC Ahll DEPRE SSANTS ~A Y POTEN11A1E THE ADV~RSE EFFECTS OF ~ADI 
AN{l ET RYL ALCG~UL ANO T~E PH ARMA COLOGICAL EFFECTS OF SYMPA THOMIHET IC S, 
T~YWGIO PREP~R~flONS, ANTIHISTAMINES AhD ANTICHOLINERGICS. TH EY HAY ANTAG-
ONI Zl GUANEThIOlNE. BARB ITURATE S AP PEAR TO DEC REA SE THERAP EUTI C ACTIVITY. 
Th EY ARE POTE NTI ATED BY METHYLPHENIDA TE. URINE AC I DIFYI NG AGENTS CECREASE 
REhAl REABSORPTICN AND ~RI NE ALKALINIZ I NG AGENT S I NCKEASE REABSORPTI ON. 
ANTIHISTA ~TNES MAY PKOOUCE ACOITIVE CNS DEPRESSANT EFF ECTS WHEN USED 
CONCOP ITANTLY WITH ETHYL ALCO hO L, BARB ITU RATES ANU PHENOTHIAZINES. THEY 
MAY PO TE NT IA lE T ~E PHA R~ACOLOGICAL ACTIVITY Of ANTICHOLINERGICS ANO THE 
ACV ERSE EFF ECTS GF TRICVCLIC ANTIDEPRESSANTS. 
ANTI HYPERlENSIVE AG EN TS MA Y BE POTENTIATEO BY METHU TRI MEPRAZINE (LEVC-
PROMEJ, PROCAINAMICE (P RONESTYL } AND PROPRANOLOL l1NDERALI. 
ASCORBIC ~CID ( UR INARY ACIDIFIER) MAY ANTAGONIZE AMPHETAMINES AND 
TRICY CLIC ANTICEPRESSANTS. 
( 
( 
( 
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BARBIURAT[S-ADDITIVE EFFECTS MAY BE SEEN WITH THE CONCOMITANT US E OF 
ANTIHISTAMINES, PHENUTHIAZINES AND GTHER CNS DEPRESSAl'TS . THEY MAY BE 
PGTENTIATED EY PROCAkBA ZINF CMATULANEl . TH EY PAY DECREASE THERAPEUTIC 
EFFECTS OF ORAL ANTICOAGULANTS, TMlCYCLI C ANTIDEPRESSANTS AND GRISEO-
FULVI N. THEY ~AY VARIABLY EFFECT SERUM OIPHENYLHYOANTCIN LEVELS. 
BIShYDROXYCOU~AR IN PA Y POTEN1IATE THE SULFONYLUREAS AND INC REASE SERUM 
LEVEL S OF DlPHENYLHYDANTOIN. IT IS POTENTIATE D BY ACETAMINOPHEN, ESTRO-
GE~S. ANABOLIC SIERO IDS, CHLORAMPhENICOL, CHOLESTYRAMlNE (CUE MIOJ , CLOFl-
BRATE lA TROMID S I, D-THYROXINE, PHE~YLBUTAZONE IBUTAZOLIDINl AND PH ENY-
RAMIOOL !ANALEXIN). IT MAY UE POTENTIATED BY AMINOGLYCOSIOE ANTIBIO TICS, 
CIPPEN YLHYCA~TCI~. I NDGHETHAC IN AND SALlCYLATES. IT IS ANTAGONIZED BY 
ETHYL ALCOHOL, BARBITLRATES, ETHCHLORVYNOL, GRI SEOFULVIN AND GLUTETHI MIDE. 
IT IS VARIAHLY AFFECTED BY CHLORAL HYDRATE. 
eISACOOYL lDL LCOLAXl TABLETS S~OULD NOT BE TAKEN CONCOMITANTLY WITH 
ANTACIDS. 
CALCI U~ ICNS ADMINlSTERtD PARENTERALLY MA Y PHARMACOLCGICALLY POTENflATE 
DIGITALIS GLYCOSIDES. 
CAR BENICILLIN (PYOPEN, GEOPE N) PLAS~A LE VELS MAY BE ELEVATED ANO PRO-
LONGED BY PRCBENECIC CBE NEM lD ). 
CEFHALOSPCRINS, ALL-PLAS MA LEV ELS AKE ELEVATED BY PROBE~ECIO !BE NEMIO>. 
CO~ CO~ITANT tDHINISTRATION OF CEPHALOTHIN AND COLISTIN INCREASES INCIDENCE 
GF NEPHROTOXICITY. 
( 
( 
CHLO RA L BETAINE (BEJA- CHlU Rl VARil,B LY EFFECTS THE ANTICOAGULANT 
R ESfC~S E TO CkAL ANTIC OAGULAN TS. 
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CHLORAL HYDRATE VARIABL Y EFFECTS THE ANTICOAG ULANT RESPONSE TO ORAL 
Afl.TJCOAGULA NTS. 
CHLGRAMPHENlCOL PAY POTENT IATE ORAL ANTICOAGULA ITS, DIPH ENYLHYOANTO fN 
AND SULF ONY LLREA S. 
DlU RE TIC S F ~UCUCING POTASSJU~ AND PAGNES I UM DEFIC I ENCIES MAY PRECIPI-
TATE D!GlTAllS lOXIClTY. CONCOMITANT USE Wl TH CC RTICOSTERO IOS MA Y RESULT 
IN EX CESSIVE POTASSIUM LOSS. DIURETICS MAY ANTAGON IZE THE ACTIVITY OF ORAL 
HYPCGL YCEt·~ IC S. 
CHOL ESTYKAM!fl.E !CUE~lOJ MAY ELEVATE THE ANTIC OAG ULANT RESPONSE TO O~ AL 
AhTICOAGULARlS. IT DECREASES ABSORPTION OF THY RCID PREPARATIONS BY 
Blfl. CING lHY RCXINE ANO TKIIODOTHYRC NN INE. 
CLOFIBR ATE (ATROMID Sl PHARMACOLCGICA LLY ELEV ATES THE ANTICOAGULANT 
RESPONSE TO CRAL ANTICOAGULANTS. IT ~AV INHIBJT PLATE LE T ADHESIVENESS. 
COLIS1I N (COLIMYCINJ ENHANCES NELROMUSC~LAR BLOCKADE OF SKE LETAL MUSCLE 
RELAXANTS. CCNCOMITANT AD I INI STKA TI CN CF PAREhT ERAL CEPHALCS PCR lNS 
INCREASE S I N CICE~CE OF NEPHROTOXI CI TY. 
CORTIC OSTERGIDS KAY BE POTENTIATED BY ESTROGE NS. THEY ~AY PHAKMACOLO GI-
CALLY ANTAGONIZE HYPO G LYC E~ ICS ANO DECREASE SALIC YLATE PL ASMA LEVELS. 
CIPH ENYL HYDANlOIN MAY DECREASE THERAPE UTIC RESPONSE TO CORTICOSTERO IDS. 
CONC OMlTANT CSE hITH DI LRE TICS ~AY PESLLT IN EXCESSIVE POTASSIUM LOSS. 
( 
( 
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CORTICOTRCPIN !ACTH) MAY BE POTENTIATED BY ESTROGENS. IT MAY PHARMA-
CCLOGICALLY ANTAGO l I ZE hYPOGLYCHICS AND DECru: ASE SAUCYLATE PLASMA 
LEVELS. C!PhENYLhYUANTOIN MAY DECREASE RESPONS E TO CORTICOSTEROIDS. CON-
CCMITANT USE WITH ClURETICS HhY kESLLT IN EXCESSIVE POTASSIUM LOSS. 
DAPSONE {tVLUSULFONI PLA SMA LEVELS ARE INCREASED BY PROBENEC1D 
(Bf.rEMID). 
DIGITALIS GLYCOSIOES ARE PHARMACOLO GICALLY PCTENTIATED BY PARENTERAL 
CALCllJI~ PREPARl\TIOt-;S f>.ND DIURETICS PRODUCING POHSSIU~ ANO MAGNES IUM 
DEFICIENCIES. AMPHOTERIClN B (FCNGlZ GN E} ~AY PRODUCE HYPOKALEMIA 
PRECIPITATIN( ClGITALIS TOXIC~TY. SYMPATHOMIMETICS ~A Y I NCREASE lNCICENCE 
OF CARDIAC A~RFYTHMIAS. 
ClPHENYLHYOANTOIN IS POTENTIAl EO BY CHLORAkPHtNICOLo DlSULFIRAM 
IANTABUSEJ A~D ISDNIAZID. IT MAY BE ANTAGONIZED BY ETHYL ALCOHOL AND 
PHENYRAMI DOL IA NALEXINl. I T MAY POTE~TIATE ORAL ANT IC OAGULANTS AND 
METHOTKEXATE. IT MAY CECkEASE THE THERAPEUTIC RESPONSE TO CORTICGSTEROIOS. 
CIPYRIDAMCLE ( PERSANlI~EJ ~AY POT ENTIA IE THE ANTICOAGULANT AC TIVlTY CF 
HEP /IRIN. 
DISULfIRA~ (ANTA BU SE J POTENTIATES DIPHENYL HYOANTOIN. CONCOMJTANT USE 
WITH ISO NI AZlU , ETHYL ALCUHGL ANO METRON IOAZOLE (F LAG YL) ENHA~CES THE 
INCIDE NCE OF ADVERSE EFFECTS. 
ECfOTHinPrATE IODIDE (PHOSPHCL I NE I 00[0E) .POTENTIATES THE PHARMACOLOGI-
CAL EFFECTS CF SUCCINYLCHOLI NE. 
( 
( 
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EPHEDRI NE PDTENTIATES HYPERTENSIVE REACTIONS WITH MAGI. IT ANTAGONIZES 
ThE ACREN~RGIC NEURGN BLOCKACL PRODUCED BY GUA NE THIDINE II S~E LlN). 
EPINEPH RlNE, AND TO A LESS ER EXTENl, CT HE~ ADR ENERGIC AGENT S MAY 
DECREASE ACllVITY OF HYPOGLYCEMIC AGENTS. 
ESTROGENS PHA RMACOLOGICAL LY ELEVATE THE ANTICOAGULANT ACTIVITY CF ORAL 
ANTICOAG~LANTS. TH EY ~AY POTENTIATE CORT!CCSTERCID ACTIVlTY. 
ETHAC RYNI C ACID PG TENT IA TES CTOTOXIC ITY OF AMINOGLYCOSIOE ANTIB IOTICS. 
IT ~AY PHO~UCE POTASSIU~ AND MAG~ESIUM OE FICIEhCIES PRECIPITATING 
OIGllALI S TOXICITY. CGNCO MI TANT USE WITH CURTICCSTEROIDS MAY ENHANCE 
PCTASSJU M LGSS. IT MAY ANTAGONIZE TH E ACTIVITY CF ORAL HYPOGLYCEMICS. 
ETHC HLORV~NC L ( PLACIOY Ll ANT•GONIZES THE ANTICOAGULANT ACTIVITY OF ORAL 
ANTIC CAGU LA NTS. 
FOLIC ACIG ANTAGONIZES THE AN11NEOPLAST1C ACTIVITY OF PETHCTREXATE. 
FUROS EMIDE MAY PRODUCE POTASSIU M ANO MAGNESIUM DEFICIENCIES PRECIPITA-
TING DIGITALIS TOX ICITY. CO NCOMITANT USE ~ITH CORTICOSTEROIDS MAY ENHANCE 
POTASSIUM LOSS. IT ENHAhCES ThE EFFECT S OF TUBOCURARINE. IT MAY ANT AGO~ IZE 
lHE ACTIVITY OF CRA L HYPOG LYCE MICS. 
CENT AMlCIN I N CO MBINATION WlTH OTHER AMINOGLYCOS IDE ANTIBIOTICS 
INCREA SES INCICENCE OF CTOTOXICITY AND NEPHROTOXfCITY. ETHACRYNIC ACID 
POTENTIAlES THE GTOTOXICITY. IT ENHANCES THE BLCCKACE OF SK ELETAL MUSCLE 
RELAXANTS. 
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GLUTElHIMIDE !DORIDENI DECREASES ANllCOAGULLANT RESPONSE TO ORAL 
ANTICOAGULANTS. 
GLYCERYL GUAIACOLAlE MAY PGT[~TIATE lHE ANTICOAGULANT ACTIVITY OF 
GRISEOFULVIN MAY DECREASE THE ANTICOAGULANT ACTIVITY CF ORAL A~Tl-
COAGULANTS. IT IS ANTAGONIZED BY BARBITURATES WHICH MAY IMPAIR ABSORPTION . 
GUA NE TH!DINE MAY BE POTENTIATEO BY PROCAI~AMI OE, PROPRANOLCL ANO 
QUl~JDINE. 11 IS ANTAGO~IZED BY AMPHETAM[NES, TRICYCLIC ANTIDEPRESSANTS , 
EPHEDRI NE ANC METHYLP~ENIOATE . I T MAY POTENTIATE PHENYLEPHRINE AND 
DECREASE ACTIVITY OF HYPOGLYCEMICS. ETHYL ALCOHCL AND METHOTRIMEPRAZINE 
(LEVOPROHEJ, PROCARBAZINE (~ATUL AN E) AND THIAZIDE DIURETICS MAY POTENIIATE 
CRT~CSTATI C hYPGTENSlON. 
HEPARIN I~CUCED ANTICOAGULANT ACTIVITY ~AY BE E NHA~C ED BY DIPYRIOAHOLE 
( tPERSA NTINEl AND GLYCERYL GU AI ACOLATE. 
CRAL HYPCGLYCEHIC AGENTS HAY BE POTENTIATED BY CHLORAMPHENICCL, MAOls 
PHE~YLBUTAZO~E lBUTAl ULIDINl • PROPRANGLOL llNOERAL J , BISHYOROXVCOUMARIN, 
PHENYRA MIOO L IANALEXl ~ l ANO SALICYLATES. THE HYPOGLYCE MI C EFFECTS AR E 
A~JAGUNIZEO BY CC RTICCSTEROIOS, DIURETICS AND GUANEJHIOINE (ISMELINl. 
INOOMETHACIN ~AY PHARMACOLOGICAL LY ELEVATE THE ACTIVITY CF ORA L ANT I -
C O~GLLANTS. INDOMETHACI N PLASPA LEVEL S MAY BE I NCREASED BY PROBENECIO 
{ BE~EMIOl ANC CECREASEO BY SALIC YLA TES . 
( 
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INSULIN MAY BE PHARMACOL OG ICALLY A~TAGONIZED BY GUANETHID! NE. ETHYL 
ALCCH CL MAY PROLONG lHE ACTION Of INSULIN. GLUCOCORTICOIOS , THYROID, 
lPINEPHRI NE ANG T~IAZIDE DILRETICS ~AY I NCRE ASE I~ ULIN REQUIRlMENTS. 
IRON SALTS SHCLLO NOT BE U~EG SI~U LTA N ECUSLY ~ITH ALLOPURI NO L 
I ZYLOPRIMJ. ANTACIDS PA Y DEC REA SE IRON ABSORP TIO N. IRON SALTS MA Y IMPAIR 
THE ABSORPT ICN OF ORA L TET RA CYCLIN ES. 
lSONIAZID INC REAS ES PLAS MA LEV ELS OF CIPHENYLHYDANTOIN. IT MAY BE 
A~lACONI ZEU BY ETHYL ALCOHOL. CONCO~IlANT USE WITH OISULFIRAM !ANTABUSE) 
AND ~LPE~IO!~E ENHANCES INCI DEN CE OF ADVERSE EFFECTS. 
C-THYROXI~ E ELE VATES THE ANTICOAGULANT RESPONSE TO ORAL ANTICO•GULANTS. 
ISCPROTERENCL IS PHA RMA COLOGICALLY A ~lAGONIZED BY PRCPRANOLOL {I NOERA LJ 
KANA ~YCIN IN CO MB I~ATICN ~ ITH GTHER AMI NOGLYCCSIDE ANTIBICTICS 
INCR EA SES INCI CENCE UF CTUICXIC l TY AND NEPHROTOXICITY. CO NCO MITANT USE 
WIT~ ElHACRY~IC ACI D PCTENTIATES THE OTCTO~ICI TY. IT PO TENTIATES NEURO-
MUSCULAR BLOCKADE OF SKELETAL MUSCLE RELAXAN TS. hHEN ADMINISTERED BY THE 
ORAL ROUTE IT MAY INC REASE THE AC fI VITY CF ORA L AN TICO AGULANTS. 
KAOL IN-PECTIN MIXT UR ES INHIBIT TH E ABSO RPTION OF ORALLY ADMINISTERED 
LI NCCMYCIN !LI NCOCINJ. 
LEVODOPA ~AY BE ANTAGONIZED BY METHYLDOPA , PYRIDOXINE, RESERPINE AND 
PH ENOTHIAZINE S. CONCOM II ANT USE ~ITH MAOI MAY PRODUCE HYPERTENSION. 
ADDITIVE THERAPEUTIC EFFECTS MAY OCCUR hlTH AMANTADIN E ISYMMETREL). 
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LIT HIUM EXCRETION 15 I NCREASED BY A ~ INOPHYLLINE, SODIUM BICARBONATE ~ND 
LA RGE DOSES CF SLDILM CHLORIDE. LC W SODIUM INTAKE HAY PRECIPITATE LIT HIUM 
TCXICITY. 
~ AGN ESIUM IONS ACMINISTERED PARENTERALLY POTENTIATE TtlE NEURCMUSCULAR 
BLOCKADE OF SKELETAL MUSCLE RELAXANTS. 
~EPERIDINE S! ICULJ NOT BE USED SI~ULTANECUSLY WITH lSONIAZID AND MAOI -
IT ENHANCES INCIDENCE OF ADVERSE EFFECTS. IT IS POT ENTIATEO BY CTHER CNS 
DEPRESSANTS. 
~EFRCBAMATE IEQUANI L,MILTO~N! IS POTENTIATEO BY ETHYL ALCOHOL. 
~EICAPTOPURINE !PURINETHOLl IS POTENTIATED BY ALLOPURINOL (lYLOPRI Ml. 
~ETARAMINCL I ARAMINE) IS PH ARMACOLOG ICALLY PClENTIATEO BY ~AOI. 
METHENA~I~E CG~PCU~US EXHlBll OPTIMUM ACT£VITY lN A URINE PH OF 5.5 CR 
L O~ER. URINE ACIDlFYI NG AGENTS ARE LSEFUL AOJLNCTS WHILE URINE ALKALIN-( IZ ERS DECREASE ACTIVITY. CONCOM!TANf USE hITH SULFONAMIDES FREQUENT LY, 
RE SULTS IN CRYST ALLLRIA AND THE FGRMATICN OF A PRECIPITATE. 
~ET HC T RE XATE SERUM LEVELS ARE ELEVATED BY D!PhENYLHYDANTOIN, 
SALICYLATES AND SUL FON AMIDES. IT MAY IMPA IR T11E IMMUNOLOGlCAL RESPONSE 
TC SMALLPOX VACCINE, RESULTING IN VACCINA. 
~ETHCTRIMEPRAZINE (LEVOPRO ~E l POTENTIATES THE EFFECTS OF ANTIHYPER-
TENSIVE AGENTS, OTH ER CNS DEPRESS AN TS ANO SKELETAL MUSCLE RELAXANTS. lT 
WI LL PRODUCE EXTRAPYRAMIDAL SY MPTOMS WHEN USED SI MU LTA NEOU SLY WI TH 
A~TICHOLI N ERGICS. 
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METHYOXYFLURANt ANESTHESI A IN CONJUNCTION ~ITH TElRACYCLINE THERAPY 
I NCREASE S INCICENCE OF NEPHROTOXIC EFF ECTS. 
~ETHYLOOPA MAY ANTAGCNilE THE THERAPEUTIC EFFECTS CF LEVOOCPA. ACG ITIVE 
HYPCTENSIVE EFFECTS MAY OCCUR WllH PROPRANOLOL (JNOERALl~ PROCAIN AM IOE 
( PRGNESTYL), MET ~OT~I MEPRAZ INE !LEVCPROME) AND lHIAZI OE DIURETICS. 
~ETHYLPHENIDATE {RlT ALtNJ POTENTIATES TRICYCLIC ANTIDEPRESSANTS. IT MAY 
BE POTENTIATED BY MAO!. IT ANTAGONIZES THE PHARMACOLOGICAL EFFECTS OF 
GUANETHIDI NE !I SrELINl . 
~ ETkONIDAZlLE {FLAGYLI SHOULD NOT BE U~ED sr~ULTANEOUSLY WITH 
CISULFIRA~ (ANTADUSEJ OR ETHYL ALCOHOL DUE TO THE INCREASED INCIDE NCE OF 
ADVERSE EFFECTS. 
PONOA~INE OXICASE I N ~IBIT OR S POTENTIATE THE rHARMACULOG ICAL EFFECTS CF 
AMPHETAMINES , METHYLP~ENIDATE ! RI TALINI, TRICYCLIC ANTIDEPRESSANTS, HYPO-
( GLYCEMICS ANC SY~PATHCMIMETICS SUCH AS EPHEDRI~E, METARAMINOL !ARAMINE}, 
PHENYLEP HI INE AND PH EN YLPROPANOLAMINE. CONCOHIT A ~T USE WITH HEPERIDINE OR 
LEVCDOP A INCREASES INCIGENCE CF ADVERSE EFFECTS. 
~A F CILLIN (UNIPEN) PLAS MA LEVELS ARE INC MEASED BY CONCO~ITANT USE OF 
PROB EN ECIL ( PENEMIO l. 
NEOMYCIN IN COMBINATION WITH OTHER AHINOGLYCOSIOE ANTIBIOTICS INC REA SES 
INClC ENCE OF OTOTOXICITY AND NEPHROTOXICIT Y. CG~COMITANT USE ~ITH 
f ET~ACRYNIC ACID PO TEN TIATES THE OTOTOXICITY. IT POTENTIATES ~EURONUSCULAR 
BLOCKADE OF SKELETAL MUSCLE RELAXANTS. hHEN ADMINISTERED BY THE ORAL ROUTE 
IT ~AY INCREASE THE ACTIVITY GF ORAL ANTICOAGULANTS. 
• 
1 ( 
( 
( 
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NITROGLYCERIN ~AY PRODUCE HYPOTE NSICN FCLLC W I~G COM BINEC USE WITH ETHYL 
ALC UHOL. CHRCNIC AD MINISTRATION OF PENTAERYTH RITOL TET R A ~IT R ATE CPER1-
TRATEJ VAY PROCUCE A TOLER ANCE TG NITPCGLYCERIN. 
CRPHENACRINE ( NORFLEX! IN CO ~U l N ATlON WITH PROPOXYPHENE (DARVON) MAY 
PROUUC E MEN TAL CONFUSIO~ AND ANXIETY. 
OXYPHENBUTAZOhE (TANCE ARILl ELEVATES THE ANTICOAGULANT RESPONSE TO ORAL 
ANTICOAGULANTS. OXYPHENBUTAZONE PLASMA LEVELS HAY BE ELEVATED DY ANABOLIC 
STER CIDS. 
PENICILLIN G AND DERIVATIVES-PLASMA LEVELS ARE ELEVATED BY PROBENECID 
( BENEMIDl ANO SALICYLATES. 
PENTAERYT~RITOL TET RANITKATE {PERITRATEI THERAPY MAY PRODUCE A TOLER-
ANCE TO NlTRCG LYC ERIN. 
PhENOThlAZINES MAY A~TAGONIZE LEVODCPA AND THE CENTRAL EFFECTS Of 
AMP~ET A~lNES. ADDITIVE Ef FECTS CCCUR ~ !TH CONCOMITANT USE OF OTHER CNS 
CEPRESSANTS AND ANTlHISlAMihES. AOOITIVE CAROlAC DEPRESSANT EFFECTS ARE 
POSSIBLE W IT~ QUINIOI~E. PROCARBAZINE IMATULANE) MAY PUTENTIATE TH E 
CNS CEPRESSA~T EFFECTS OF PHENOTHIAZINES. 
PHENYLOUTAZCNE C OUTAZOLIOI~l ELEVATES TH E Al ' TICOAGULANT RESPONSE TO 
ORAL ANTICOAGULANTS AND P8TENT1ATES THE HYPOGLYCEMIC RESPO NSE TO SULFONYL-
UREAS. PHENYLBUTAZG hE PLASMA LEVELS MAY BE ELEVATED BY A14ABCLIC STEROIDS. 
PHENYLEPHRINE ADMIN IST ERED NASALLY OR SYSTE~ICALLY MAY BE POTENTIATED 
BY GUANETHlDINE !ISMELINl ANO MAO!. 
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PHENYLPRGPANOLAMINE ~AY BE POTENTIATEO BY KADI. 
PHENYRAMlCOL IANALEXINl EL~VAlES THE ANTlCOAGULA liT RESPONSE TO ORAL 
ANTICOAGULANTS A~O POTENTIATES THE ACTIVITY OF DIPHE NYLHYDANTOIN AND 
SULFONYLU KEAS . 
POLYMYXlN B IAERCSPGRI ~ l ENHANCES NEUROMUS CULAR BLOCKAGE OF SKELETAL 
MUSCLE RELAXANTS. IN CO ~BINATION hITH OTHER AHINOGLYCOSIDE ANTIBIOTICS 
IT INCREASES INCIDENCE CF OTOTOXICilY ANO NEPHROTOXIC ITY. 
PROBE~EClr IBE NEklD ) ELEVATES PLAS~A LEVELS OF AMINOSALICYLIC ACID , 
DAPSONE ! AVL CSL LFON I, CEPHALOSPCRINS , PENICIL LI N G AND DERIVATIVES ANO 
INDGME THACIN . SALICYLATES INHIBIT URICCSURIC ACTlVITY OF PROBENECID. 
PROCAINA~IDE !PRONESTYLJ - ADDITIVE HY~UTENSIVE EFFECTS MAY OCCUR WITH 
CONCOMITANT USE CF AN TIHYPERTENSIVE AGENTS. 
PRUCARBA ZI NE I MA TULA~ El ~AY POTE~TIATE THE EFFECTS OF PHENOTHIAZINES 
( ANO CNS DEPRFSSANTS. IT MA Y PRODUCE AUDITIVE HY POTENS IVE EFFECTS WI TH 
GU ANETHlC INE IIS~ELINl. 
PROPOXYPHEN~ ! DARVGN l I N CUMBINA TI CN WITH CRPHENADRlNE ( NORFLEXl MAY 
PROCUCE MENTAL CONFUSION AND ANXIETY. 
PROPRANOLCL llNDERAL) MAY POTENTIATE ORAL HYPOGLYCE MICS AND ANTI-
HYPERT ENSIVES. IT A~TAGONIZES PHARMACULCGICAL ACTIONS OF SYMPATHOM I ME TICS. 
FROPRAN ULOL- I N[UCED ADVERSE EFFECTS ARE ANTAGCNIZED DY ANTICHOLINERGICS. 
ACO I TIVE CARCIAC DEPRESSANT EFF ECTS ARE POSS I BLE WI TH QUlNIOINE AND PHE~O-
T~IAZINES. 
( 
\ 
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PYR IDGX JNE !VIT AMIN 86 ) ANTAGONIZES THE PHARMACOLOGICAL EFFECTS OF 
LEVOOOPA. 
CUINIDINE MAY POTENTIATE GUANETHIOINE, ORAL ANTICOAGULANTS ANO THE 
~EURCMUSCULAR RLOCK nOE OF MUSCLE RELAX AN TS. IT MAY BE POTENTIATEO BY AN TI-
CHOLINERGICS. ACETAZOLA ~ IOE ICIAMOXlt SODI UM BICARBONATE A~D THIAZ!LlE 
CI URETJCS INCREASE RENAL REABSORPTICN. ADDITIVE CARDIAC DEPRESSANT EFFECTS 
ARE POSSIBLE WITH PROPRANULOL. 
~ESERPl~E rs POTENIIaTED OY ~ETHOTRIMEPMAZI~E (L EVOPRO ME). IT MAY 
AKTAGONIZE T~E EFFECTS OF LEVOOCPA. 
SALICYLATES ELEVATE THE ANTICOAGU LAhT RESPONSE TO ORAL ANTICOAGULANTS , 
INCREASE PLASMA LEVELS OF UNBCU ND PENI CILLI N G AND DERIVATIVES ANG 
PGTENTIATE METHO TRE XA TE AND SCLFCNYLUKEAS. SALICYLATE PLASMA LEVELS MAY 
BE DCCREASED BY COR TICO ST~ROIGS. THEY MAY DECREASE SE RUM LEVELS OF INDO-
METHACI~ (INCOCI~J ANC INHIBIT lRICCSURIC ACTIVITY OF SULFINPYRAZ01 'E 
tA NTURA~El A~D PROEE~ECIO CBE NE~ID J. 
SUKGJC AL SKELETAL ~USCLE RELAXAN TS ARE POT E~ TIATED BY AMINOGLYCOSIDE 
ANTIBI OTICS 1 AMPHO TERI CIN B, FU ROSEH IDE, MAGNESILM IONS, METHCTRIMEPRAZINE 
(LEVGP RCKE l, QUINIDINE AND THIAZIDE DIURETICS. ECHOTHIOPHATE IODIDE 
PCTENTIATES THE EFrEC1S OF SUCCINYLCHOLINE. 
SMALL POX VACCINATION MAY RESLLT IN GENERALIZED VACCINA WITH CONCUMI -
TA NT USE OF ~ETHCJREXATE. 
( 
( 
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SCCIUM BICARBONATE ELEVATES SERU~ LEVELS Of AMPHETA~lNES, TRICYCLIC 
ANTICfPRE SSA~TS ANO QUl~IDINE BY ENHANClNG RENAL READSORPTION. IT MAY 
A~TAGONI ZE METHENA~INE CO~POUND S ANO LITHIU M CAP BONATE AND DECREASE GRAL 
ABSCRPTICN OF TETRACYCL!NESb 
SODIUM CHLORICE· IN LAKG E DOSES MAY ANTAGONIZE PHAR~ACOLOGICAL EFFECTS 
OF LITHIUM CARBO~ATE. LCW s oo r u~ INTAKE ~AY PRECIPITATE LITHIUM TOXICITY. 
SCDIUM POLYST YKE~ E SULFO NAlE RESIN (KAY EXA LATE} BINDS MAGNESIU~ ANO 
CPLC!UM ID~S FOUND IN ANTACIDS RESULTING IN SYSTEMIC ALKALOSlS. 
SlR EP TOMYCIN IN CO MB INATIO N ~ITH A ~ INOG LYCOSIDE ANTIBIOTICS 
lNCME•SES INCIDENC E OF CTOTO XICITY AND NEPHROIOXIClTY. ETHACRYNIC AC I D 
POTENTIATES THE OTOTOXICITY. IT POTENTIATES NECRCMUSCULA R BLOCKADE OF 
SKELETAL MUSCLE RELAXANTS. 
SULFIN PYR tZCNE lANTURANEl INCUCED URICOSURIA IS INHIBITED BY 
SALICYLAT ES . 
SULFC NAMI CES ~AY PClENTIATE THE HYPOGLYCEMIC RESPONSE TO ORAL HYPO-
GLYCE MICS ANC ELEVAll SE UM LEVELS OF METHCTREXATE. CONCOMITANT USE WITH 
METPE~A~ I NE COMPOU~DS FREQUENTLY RESULTS I N CRYSTALLURIA AhD THE FOR~ATION 
Of A PRECIPITATE. 
TET~ACYCLIN E ABSORPllON IS DECREASED BY ANTACIDS CO NfA INING DIVALENT 
OR TRIVALENT CATIONS, SCOIUM BICARBONA TE A~D IRCN SALTS. IT MAY ELEVATE 
ANTICUAGLLA~l RESPONSE 10 ORAL Ah TICOAGULA NTS A ~ D POT ENT IATE hEPHROTOX l C 
EFFECTS OF ME THOXYFLURANE ! PENTHRANE) . 
( 
( 
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ThlAZICE CIURETICS MAY PRECIPITATE DIGITALIS TOX ICI TY AND ANTAGON IZE 
TH E EF~ECTS CF HYPOGLYC EMICS. NE L RO~USCU LAR BLOCKAUE PRCOU CEO BY SURG ICAL 
MLS CLE RELAXANTS MAY EE ENHA~CEC. CG NC OMIT AN T US E ~I T H CORTICCSTE RO ICS MAY 
RESULT IN EXCESSIVE POT ASSIU M LCS S. lHEY HAY PRODUCE ADD I TIVE HYP OTENSI VE 
EFF ECTS h llH GUANETHIDI~E ! IS~ELIN) AND ~ETH VLCCPA IALDOMETJ. 
THYRC IO PREPAHATIO~S ~AY PCTCNTIATE THE ANTILOAGLLA~ l RESPCNSE TO ORA L 
ANT ICOAGULANTS. CHULESTYRAMINE DECREASES ABSORPT ION BY BINDING THYROXINE 
ANC T KllUDGTHYRUN~INE. TH EY MA Y DE CREASE ACTIV ITY OF HYPOGL YCEM I C AGENTS~ 
( 
APPENDIX VI 
Compute r Program 
- 11 J.-
LI i\E NO . SEQ . NO . 
l OC LO 10 
2 OC l O?O 
3 001030 
lt 0C l 040 
~ l~l: iO~u 
6 CC l O'::O 
7 oc l 0 70 
8 001_0 2 0 
') 0010<;0 
l C CC l LCO 
1 1 OCl l lO 
12 OC\120 
13 0Cll30 
14 OC l l'· O 
ts OC1 150 
16 tJC l l 60 
17 OCl 170 
1 8 CC20 LO 
l c; OCZ020 
2C OC2030 
21 002040 
22 002050 
23 oczccc 
2lt 00:206 1 
2? co~:o62 
26 002()63 
27 OC2 0 ft, 
28 002065 
( 20 0(20 70 JC 002000 
3 1 oczoc;o 
32 CC21CO 
3 .~ Or:2 _ll 0 
34 OC2 1 20 
35 CC2130 
36 0 ( 2 1"1 0 
3 7 OC2 l 50 
3H OC2 16C 
3S OC21 70 
'•0 00 30 10 
41 00 3020 
42 OC3030 
43 OC3040 
41, OC30'.>0 
'• 5 00060 
4 6 OC3070 
47 CC30 fi 0 
48 OC30 9 0 
4S CC 31CO 
50 OC3 11 0 
5 l OC3120 
52 003 1 ?. 5 
5 3 OCJ 1 3-0 
51, CC31Lt0 
-~ 
SUURCF srA r EMFN T 
!f~EN TIFIC.\TlU N Dl V! S[!)N. 
Pl-!UG1<.AM -I [. ' GLn :<PT '. 
ALTHCH . ~ E PLAT!;\U ,; C D M;\HONEY . 
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CBD CL3-7 03/20/ 7 Z 
RE~4~KS. SA~ PLF F~GG~AN FOR K[ fRIEVAL OF ORuG-ORUG I NTFRACT ION 
Sl.M h\i'.1<:S \d lr1 SAl-P LE PRClF lL f . 
E~ VI kONME~ T D!V!~ION . 
CCNFIGURAT i nN SECT!GN. 
SCU!{ C[ - CU1"' PLlTI\ . f f-ll-·~-360 E30. 
OQ JECT-CO MPC TE~. l HN - 360 E30 . 
l~Pl.f-UUT?UT SEC TI ON . 
F f LE- CONTROL. 
SE LE CT CA RO ASS1GN TC ~sYS004' UN! T-kECnRO 2540R. 
SE LECT PR ! NT AS~IGN TC 1 SYS005 ' UN! T-RECORO 14 03. 
SELECT Ol ~K ASS J l~ r~ TC ' SYSOl I' iJ ! RECT-f\C CESS 23 l 4 
ACCESS lS RM,D OM1 OHCl,Nll. !\TI CN IS !NDEXf:O, 
RESERVE NO AL TERNdTE AREA, SYP S CLlC KEY IS RE C-I n , 
RECORD KEY IS OSK - NU . 
L: n A 0 I \i I S !UN . 
F IL E SECT I ON . 
FL CARO 
0 1 
Rt:CU?C C tlr~ r -~u;s .30 CHARAC Tf::fZS , LABEL RECGRC ! S UH ITT FO , 
OAf;\ r< ECU RO rs cc , RECCKO·ING MOUE IS f'. 
c [' . 
0 2 CO-IN P l CTlRE X(79 ). 
02 CGDE PIC TURE x. 
88 HhJ VA LUE t A'~ 
88 MEO VAL UE 'f.3 ' '> 
38 O!-'. r VALUE 'c •. 
F[. PR i l'. T 
RECORD CONT A l~S l 33 CH AHAC TE RS, LABEL HE CO RO IS OM!lT EO , 
DAJA RE CORD IS PRT , RECOKD I NG MOVE IS F . 
Cl PKT P! C TL RE Xll 33 }. 
FD DI SK 
RtCCRO CON TAINS 6 7 1 CHARACTE~ S , LA RE L RECORD IS ST~ND AR D , 
0;-\TA f<EClJPD r s DSK , RECC RDING HOOE IS F . 
0 l OSK . 
02 OSK - NO PI CTLRE X(5 l. 
OZ MSG , OCC URS 9 T I ~ES . 
03 DSK-~SG P!CTL RE X(741 . 
wO~K [ NG-Sl ORAGE SEC TI ON . 
17 A PICT URE S9999 
77 a P!CTLRE 5999~ 
77 C PICTURE 59999 
77 RC SW PICTURE 99 
77 LlN-CNT P I CTURE 99 
77 CC P I CTURE X. 
77 PAG - CN T PIC TURE 99 
77 r, Atv:f -STOR PI CTLRE x 12 1 l. 
CC~PU fATI ONA L VALUE 6 . 
C O~PU T AT I ON~L VALUE O. 
CO~PUTA T[ ONAL VALUE O. 
CC~PUTAf l ONAL- 3 VALUF l. 
CO MP UTA TI UNA L- j VALU E O. 
CO~PUTATfONAL-1 VALUE O. 
n P 1 - r~u - s re ~ PI CTURE 917 ) CO~PUTATIONAL-3 YALUf O. 
77 I-' T- RM-S T Ct~ I' l C TUR E xxx. 
n RE C- ID P ICTL RE x { s ). 
77 D1\Y·-S TOR PI CIU RE xx. 
Ol TMl LE . 
02 LINE, CCC URS 30 TI ~ES . 
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( 
I f\E NO. SEQ . Nl1. SCURCE s r 1\ T::xr:r-; r 
55 CCJlSC Cl H\ L-i\C P[C TL RE x ( 5 ). 
56 U C3 l 60 0 l HOS!" - HED . 
57 CC3 l 70 f)L F ILL ER PlC TUf<E XU•/ ) VALUE SPACES. 
5!J CC3120 02 T lTL (: P I CTUgE x ( 2 2) • 
59 I) O:i1 ''il) 02 fl LL EK i-' IC r c, R E x (82) V ,\ LUE SPACES . 
60 OCl1010 0 1 PT-HEC . 
Al ou.c20 02 FlLLE~ P l C T\ ;RE x (12 i IJALUE SP :\CES. 
62 004030 02 f-JLLE !< P[C1LRE X(35 ) VALUE 
63 CC'1040 ' C.Ll"ULAl IVE l' tiJ!CtdlO PKCF ! LF. fOK I . 
64 004050 02 Pf{ f-N:l.M PIC1LR[ X(2 1). 
65 OG40LO 02 FJLLEI< PICTURE X(6 5 l IJ 1\LUE SPACES . 
66 OCL1070 I) l UhDtKLINl . 
67 CC40d0 02 FILLER P l CTLl<E X(41) VALUE SPACES. 
611 OC:t()SO 02 FILLER PlCTLRf )( ( 2 l) VALUE ALL 
· -· 
. 
c<J (;(.ttl CO 02 FlLLE t~ P ICTURE X165 l VA LUE SP!\CE S. 
7C OC41 10 0 1 PT- HEO l. 
7 1 OC'+ i ;:o 02 FILLER Pl C TURE x { 12) V ALUE SPt1CES. 
72 oc4 1 ·rn 02 FILLER =>IC TL RE x (4 J VA LU E I NU . I 
7 3 OC!il '10 02 PT-NO-P R 1 PJ C1URE 9 (7). 
7 li 0 C't l ':iO 02 F ! LLER PICrURE x ll 6 ) VALUE • ROOM 
75 CC4160 02 P T-- 1< M- PR T PICTU RE xxx . 
76 OC4170 02 F IL LER PICTLt<F X (l 6 l Vt1LUE • AGE 
77 OC411'0 02 PI- AG- PH T Pl C Tt,!~f 90 , ,. 
78 QCt1 l SO 02 F ILLEH f'ICTL,l<E X(64l VALUE SP/\CES. 
79 OC5010 0 1 COL-HElJ. 
ec OC5020 02 FILLER PI C TUJ?F. X ( 8C l VA L lJE 
P. \ OC50'.rn f ST!\P T S10P Mt!J rcr.r rcr, CR DEREO 
82 0•.'.?040- I PHYSICIAN 
83 OC5G50 02 F!LLER P!CfURE x ( 5 3 ) VALUF SP1\CES . 
( 8 4 OC5Ct:'J 0 1 UNDE'KL!~1 ;~ . 85 005070 02 FILLER PICTUHE x <8 0l VALUE 
86 OG50P.G • 
----------- -------
3 7 OC5090 - I ----------
tJ(l 005 1 00 02 F ILU:r< PIC1l,RE x ( 53 ) VALUE SPACES. 
BS OC5 l 10 0 1 PRT-LIN . 
90 0(5120 02 F IL LER PIClCRE x_xx VALUE SPACES. 
9 l OC5 1 30 02 M Tit- ! N l I' IC 1L:RE x ;( . 
r, 2 OC5 140 02 FI LL ER Pl C TUf<E x VALUE 'I' • 
93 OC5150 02 DAY- f Nl P I CH .' RE xx. 
91, OC5 160 02 FlLLEJ{ P I CTlRE xx VA LUE SPACF:S. 
<; 5 CC 5 1 70 02 MfH - CU1l PIC T U<E xx. 
S6 005 1 80 02 SLASH PJCHRE x. 
97 OC5 l SO 02 0fl Y-OU1"J_ PICTURE xx . 
98 OC5200 02 FI L LER PICTURE xx VllLUE SPf,CES. 
9S OC52 10 02 PPT - mrn P1CTL RE x ( l1 b ) • 
l CO OC52?0 02 FILLER PI C T L:~ E xx . VA LUE SPACES •. 
1 01 005230 02 PiH-MD Pf CHHE X(i2 ). 
102 OC5240 02 Fl LlEk PICTLRE X {5 6i V:'ILUE SPACES. 
103 006010 0 1 P f- HEC2. 
10'1 OC6020 02 FHLEI' P I CHRE XXX VHUE S PA CES. 
105 GC6030 02 PR T-Ni-H12 PICT:.J PE :< ( 21). 
lGb OC&flt,.Q oz f ILLE"- Pl:Cfl:RE x l a l Vi\ LUE . NO • • 
10 7 0060'.>0 02 p ·r--i\ 0 -P F: TZ PlCH;i<E 9 ( 7). 
1 08 0060t:O 0 2 F l LL l:R PICTU RE X { L 7l V1\LIJE I ROOM 
' 
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( 
LI NE NO . SEQ . NCI. 
163 009030 
l t 4 UC<JOL1() 
.1 65 CCS050 
166 009055 
16 7 009056 
1 68 0(9060 
169 OCS070 
170 OCS080 
l 7 l 009090 
172 OOSOS5 
173 ccc;ico 
l 7 ' • C091 C5 
175 ccc;110. 
176 009 11 5 
J.n OCY120 
17 8 OC'J l 30 
l ., c; OO'H35 
180 CCSJ40 
H' l OC9 15C 
182 OG9 l 60 
1 8 3 OCS 1 3C 
l 8 t; 0 100 10 
135 0 10020 
186 0 l OO :~O 
18 7 Cl0 040 
urn 0 100 50 
189 0 J.0060 
190 010070 
l <J l 0 10()8 0 ( 1 92 Ol OCSG 
193 Ol Cl CO 
194 0 10 110 
195 010 1 20 
196 0 1oi:rn 
1 9 7 Cl Ol L10 
1 98 0101 50 
19 c; OlClC O 
20C 0 l 0 l 70 
} . ~ 201 01 0 175 
202 011010 
2C3 0 11015 
?04 0 11 0 16 
20 5 011020 
206 01 1030 
20 7 Cll 0'10 
2C8 011050 
20'7 0 11 060 
210 Cll 0 7 0 
211 0 11 oeo 
2 12 Cll OSO 
213 0 111 00 
2 l'1 CllllO 
2 15 0 11 120 
2 16 0 111 30 
( 
SOURCE STATEMENT 
OPEN I NPUT CARO DIS K [UlPUT PRINT. 
CCRD . 
READ CARD AT ENO GO TC EOJ • 
MOVE CO- I N TO CO-AREa. 
IF D~ T GO TU OATL-SAV . 
IF RllSW = 1 GC TC Fill ST-RTN. 
IF HEC GO TO SU~RY. 
PROt-lLE . 
IF LI N-CN T , 26 PERFORM HEO-RTN2. 
MOVL MTH- I N TLl MT H-!Nl. MC VL DAY- I N TO OAY-I Nl. 
MOVE /IEO-CRO TO flRT-CRO. 11.0VE MO TO PRT-MO. 
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If lJAY-OU T = I I MOVE 1 I TIJ SLASH ELSE 1-'0 Vf. '/'TO 
MO VE !'TH - CUT TO "1TH - CLT1. MUVE CA Y-CUT TO D/IY - CUT l •. 
PERfORM RlTE -U NE. IF OAY - fllJ f = 1 ' GO TO CHK-R TN. 
IF OAY-OUT ) DAY-STCR GO TO CORD ELSE GO TO C~K -RTN. 
f< i TE-·lINf. · . . 
~10VE PRT-L!N TO PR T. PEkFOfH' IUTE-RTN . ADD l TO LI N-C NT. 
U'K-RTN; 
IF MSG-NO = 1 ' GO TC CO RO . 
PERFO :u1 MSG·-C HK VMZV ! NG A FROM 1. BY 1 UNT IL TO L- NO (,\) = ' ' 
MOVE MSG-NO TC T B L- ~C ( Al. GO TG CORD . 
F i t~S T-RTN . 
IF ~ED GO TO CORO . NCVE 0 TC ROSW. 
PERF09M HED-RTN l. GC TG COR G. 
HEO - RTNl. 
MOVE l TO CC . MCVE ' 1".00ERN HCSP ITAL ' TC TITL E- . 
MOVE HGSP-hED TU PRT. PER FOR~ RllE-R T~ . MO VE C TO CC. 
MOVE ' DEPART~ENT CF PHAR~ACY 1 TC TI TLE. MUVF HO SP-HEO 
PERFO R ~ Rl TE- KTN. MC VE PT- NAM TO PR T-f\ AM NAME - STOR . 
MC VE PT-HED TO P~T . PEPFOPM R !T E - ~ T~. MOVE 1 ' TO CC. 
MOVE UNOERLIN l TC PRT. PERFORM RITE - RTN. MOVE~ TO CC. 
MO VE PT - NC TC P T-ND- STCR PT - NG-PR T. 
,MOVE P T- R~ TO PT- RM -STOR Pl-RM- PR T. 
~C VE PT - AGE TO PT-AG-P RT. 
MCVE PT-HEO l TO PR T. PERFQ RM RI H-R TN. 
MOVE COL-HED TO PR T. PERFCRI" r.: J TE-RTN. MQV f ' ' TO CC. 
MOVE LNCE RLl f\2 TO PRT . PE~FCR~ RIT E-R TN. 
MO VE C TO CC, A, 13 . 
MOVE 5 TO LI N-C NT. 140VE- 1 T G PAG-CN T. 
HEO--RTN2. 
MO VI: 1 CUN TINUED ON f\EX T P AG E ' TC TITLE •. MO VE 1-'0SP-HEO TO PR T. 
PE RFORM RI TE-RT N. 
MO VE 1 TO CC . MOVE 0 TO LI N-Cf\ T. 
MOVE NAME-S TCR TO PRT-~AH2 . 
~C V E PT-NC - STCR 10 P T-NC-PRTZ. 
MO VE Pf - ~~ - S T CR TO PT-RM-PR T2. 
AOD 1 TO PAG-CNT. MCVF. PAG-CN T l'O PAGE-NO • ... 
MOVE P T- HE OZ TC PR T. PERFGRN RITE-R T~. MOVE 0 
HCO - R TN3 . 
MO VE l TO CC. MCVE 0 TC L !N--{;Nl . 
MOVE NA!'f-S TCR TU PRT-hAM3 . 
MCVE P f- NC-S TCR TO P1-~0-PR T 3. 
MO VE PT-HCOJ TO PR T. PtRFCRM RIT t-R TN. 
DAH -S AIJ . 
( 
L Jr\E NO . SEQ . NU. 
n1 Oll lltO 
218 Cl 2010 
2 l 'l 0 12020 
22C Cl2Ll40 
2Zl 0 12 c '50 
222 01201.':0 
223 01 20 70 
224 012080 
225 Cl2090 
226 ClZlCO 
?27 Cl211C 
228 0 1 2120 
nci 0 12130 
230 0 12 140 
23 1 0 121 50 
2 32 012 H O 
233 0 12170 
234 Cl3 0 10 
235 0 13020 
236 01 303 0 
2.3 7 0 13040 
230 0 1 3C50 
239 013060 
24C 0 130 70 
24 1 Ol 30t:O 
24 2 ClJOSO 
zt, 3 0 13100 
2114 013 110 
245 Cl 3 1 2 0 ( 246 c 131 30 
2 47 Cl3150 
248 0 13160 
( 
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SOURCE ST/ITEMEN T 
NUVE DATE TU C/\ Tf -STCR. MCVE CAY TO DAY-STOR. GO TO CORO. 
SU-tP, Y. 
MOVE OATE-HEO TO PRT . PERFOR 11 RITE- RTN. 
SLMR Yl. 
PER~URM hEC-kTN3 . 
SL"1R Y-RlT E. 
f<Oi) l TC 8 . IF TBL-NO 18) = ' 1 GC TO ENO-RPT. 
,,:ovE TB L- NG (t) ) ro RE C-ID. MD VE 0 T C cc. 
READ CISK I N\lt\ L!.J KEY GO TO SUMR Y- RITE. 
PERFORM OSK- KI TE V/IRY I ~G C FRUM l BY 1 UN TIL OSK- MS G (C l 
I '· ADO l TO LJN-CNT. 
IF LIN-CNT , 26 GO TG SUMRYl ELSE GC TO SUHRY-RIT E. 
END- RPT. 
MOVE TEL - HED TC ?R T. l'CVE '-'TO CC. 
PERFORM RI TE-RTN. IF BOSW = 3 GO TO CLOSEl. 
PERFORM TBL- rLNK VARYI~G·A FRCM 1 BY l UNT IL A, 30 . 
P ERFCH ~ H~C- R T N l. GC TG CORO . 
LlSK-RIT C. 
MGVF OSK-l~ S G (CJ TO PRT-MSG. 
MOVE MESSG TO PRT. PERFORM R[TE - RTN. 
MOVt ' 1 TO CC . ADD l TG Ll :\ - CN T. 
TBL- BLNK . 
MOVE 1 • TO TBL-NO ( Al. 
MSG-CHK. 
fF t~SG- NO .T J L- :\0 (A ) GO TO CD RC . 
R[ TE-R TN. 
WR IT E PRT AFTER AOVA:\C I NG CC LI NE S. 
ECJ. 
MOVE 3 TO ROSI-I. GO TC SU HR Y. 
CLOS[l. 
~LOSE CA RD PRIN T DISK. 
S lOP Rt..: N. 
